<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5061-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JANUMET XR 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE,SITAGLIPTIN PHOSPHATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        168.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD International GmbH Las Piedras" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD International GmbH Las Piedras
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Janumet XR is a tablet that contains two prescription medicines, sitagliptin phosphate and metformin. Sita gliptin, a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), and metformin, a member of the biguanide class of medicines, work together to control blood sugar levels in patients with type 2 diabetes mellitus. Type 2 diabetes is also called non-insulin-dependent diabetes mellitus, or NIDDM.</p><p>&nbsp;</p><p>Your doctor has prescribed Janumet XR to help lower your blood sugar, which is too high because of your type 2 diabetes and cannot be controlled with diet and exercise alone.</p><p>&nbsp;</p><p>Janumet XR helps to improve the levels of insulin after a meal and decrease the amount of sugar made by the body. Janumet XR helps the body respond better to the insulin it makes naturally.</p><p>&nbsp;</p><p>Janumet XR may only be taken on prescription of the doctor.</p><p>&nbsp;</p><p>What else should I know?</p><p>What is type 2 diabetes?</p><p>Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems.</p><p>&nbsp;</p><p>The main goal of treating diabetes is to lower your blood sugar to a normal level. Lowering and controlling blood sugar may help prevent or delay complications of diabetes such as heart disease, kidney disease, blindness, and amputation.</p><p>&nbsp;</p><p>High blood sugar can be lowered by diet and exercise, and by certain medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp; When should I not use Janumet XR?</p><p>Do not take Janumet XR if you are allergic to the active ingredient or any inactive ingredient, have type 1 diabetes, have conditions called metabolic acidosis or diabetic ketoacidosis (increased ketones in the blood or urine) or if you have severe kidney function problems. Also do not take Janumet XR if you have conditions that can lead to kidney problems such ascertain heart diseases, certain types of serious infections with f or example high fever, diarrhea and/or vomiting(large loss of body fluids), or are going to get or receive a n injection of dye or contrast agent for an x-ray procedure. Talk to your doctor about when to stop Janumet XR and when to start again.</p><p>&nbsp;</p><p>When should I be careful taking Janumet XR?</p><p><strong>&nbsp;</strong></p><p>Tell your doctor if you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart problems, including congestive heart failure (when the heart does not pump blood adequately)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink alcohol lot (a ll the time or short-term &ldquo;binge&rdquo; drinking)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or planning to become pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a re brea st-feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a condition that may be associated with dehydration (large loss of body fluids) such as being sick with severe vomiting, diarrhea or fever, or if you drink fluids a lot less than normal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have to undergo surgery</p><p>&nbsp;</p><p>While taking Janumet XR</p><p>Cases of inflammation of the pancreas (pancreatitis) have been reported in pa tients receiving Janumet XR. Pancreatitis can be a serious, potentially life-threatening medical condition. Stop taking Janumet XR and call your doctor if you experience severe and persistent stomach pain, with or without vomiting, because you could have pancreatitis.</p><p>Consult your doctor immediately if you experience unexplained muscle pain, tenderness or weakness. In rare occasions, muscle problems can be serious, including muscle breakdown that can result in kidney da mage. The risk can be higher in patients with abnormal kidney function.</p><p>Cases of a skin reaction called bullous pemphigoid that can require treatment in a hospital have been reported in patients receiving Janumet XR. Visit your doctor if you develop blisters or the breakdown of your skin (erosion). Your doctor may decide that you need to stop taking Janumet XR.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>Janumet XR has not been studied in children and adolescent patients under 18 years of age and should not be taken by them.</p><p>&nbsp;</p><p>Use in the elderly</p><p>Janumet XR should be used in elderly patients only under regula r medical supervision.</p><p>&nbsp;</p><p>Inform your doctor or pharmacist if you</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a re suffering from other illnesses,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have allergies or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are also taking other drugs (including those bought over the counter without prescription!).</p><p>&nbsp;</p><p>May I take Janumet XR during pregnancy or lactation?</p><p><strong>&nbsp;</strong></p><p>Women who are pregnant or plan to become pregnant should consult with their doctor before taking Janumet XR. Janumet XR is not recommended for use during pregnancy.</p><p>&nbsp;</p><p>It is not known if Janumet XR passes into breast milk. You should not use Janumet XR if you are breast- feeding or plan to breast-feed. Talk to your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>How do I use Janumet XR?</p><p>Take Janumet XR exactly as your doctor has prescribed. Your doctor will tell you how m any Janumet XR tablets to take.</p><p>&nbsp;</p><p>Your doctor may need to increase your dose to control your blood sugar.</p><p>&nbsp;</p><p>Your doctor may prescribe Janumet XR along with a sulfonylurea or insulin (other medicines to lower blood sugar).</p><p>&nbsp;</p><p>&nbsp;</p><p>Take Janumet XR once a day with the evening meal to lower your chance of an upset stomach.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you take Janumet XR, swallow the Janumet XR tablets whole. Do not chew, cut, or crush the tablets. Tell your doctor if you cannot swallow Janumet XR whole.</p><p>&nbsp;</p><p>You may see something that looks like the Janumet XR tablet in your stool (bowel movement). I f you see tablets in your stool several times, talk to your doctor. Do not stop taking Janumet XR without talking to your doctor.</p><p>&nbsp;</p><p>Continue to take Janumet XR as long as your doctor prescribes it so you can continue to help control your blood sugar.</p><p>&nbsp;</p><p>You may need to stop Janumet XR for a short time. Call your doctor for instructions if you</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a condition that may be associated with dehydration (large loss of body fluids) such a s being sick with severe vomiting, diarrhea or fever, or if you drink fluids a lot less than normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plan to have surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are going to get or receive an injection of dye or contrast agent for an x-ray procedure.</p><p>&nbsp;</p><p>Diet and exercise can help your body use its blood sugar better. It is important to stay on your doctor recommended diet, exercise and weight loss program while taking Janumet XR.</p><p>&nbsp;</p><p>If you take more than the prescribed dosage of Janumet XR, contact your doctor immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you miss a dose, take it as soon as you remember. If you do not remember until it is time f or your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose of Janumet XR.</p><p>&nbsp;</p><p>Do not change the dose of Janumet XR prescribed by your physician. Talk to your doctor or pharmacist if you feel that the drug is ineffective or too strong.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>In rare cases, metformin, one of the medicines in Janumet XR, can cause a serious side</strong><strong> </strong><strong>ef</strong><strong>fect called lactic acidosis. Lactic acidosis is a medical emergency that can cause death and must be treated</strong><strong> </strong><strong>in</strong><strong> </strong><strong>the </strong><strong>hospital. Lactic acidosis is caused by a build-up of lactic acid in your blood.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Stop taking</strong><strong> </strong><strong>Janumet XR if</strong><strong> </strong><strong>you get the</strong><strong> </strong><strong>following symptoms</strong><strong> </strong><strong>of</strong><strong> </strong><strong>lactic acidosis:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You feel very weak and tired.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have unusual (not normal) muscle pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have trouble breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have stomach pain with nausea and vomiting, or diarrhea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You feel cold, especially in your arms and legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You feel dizzy or lightheaded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a slow or irregular heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your medical condition suddenly changes.</p><p>&nbsp;</p><p>You have a higher chance of getting lactic acidosis if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have congestive heart failure that requires treatment with medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink a lot of alcohol (very often or short-term &ldquo;binge&rdquo; drinking).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and don&rsquo;t drink enough fluids.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have certain x-ray tests with injectable dyes or contrast agents used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a heart attack, severe infection, or stroke.</p><p>&nbsp;</p><p>Other common side effects in patients taking Janumet XR include headache, low blood sugar (hypoglycemia), and gastrointestinal symptoms including diarrhea, nausea, dyspepsia, flatulence, vomiting, metallic taste, stomach pain, loss of appetite, ulcers or sores. In most cases these side effects occur at the beginning of the therapy and disappear without discontinuation of the treatment. If you are treated over a longer time with metformin, your doctor will test your blood regularly because a reduction of vitamin B12 may occur. In rare cases white blood cells and platelets may decrease.</p><p>There may occur as well stuffy or running nose and sore throat, upper respiratory tract infection, abnormal elevations in liver blood tests and headache. Taking Janumet XR with meals can help reduce stomach problems. However, if you have unusual and/or unexpected stomach problems, talk with your doctor. Stomach problems that start up later during treatment may be a sign of something more serious.</p><p>&nbsp;</p><p>When Janumet XR is used with a sulfonylurea medicine or with insulin, low blood sugar (hypoglycemia), due to the sulfonylurea or insulin, can occur. Your doctor will reduce the dosage of the sulfonylurea medicine or insulin. In addition, when Janumet XR is used with a sulfonylurea medicine, constipation may occur.</p><p>&nbsp;</p><p>Additional side effects have been reported in general use with Janumet XR or sitagliptin, one of the medicines of Janumet XR. These side effects have been reported when Janumet XR has been used by themself and/or with other diabetes medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions which may be serious including rash, hives, and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. If you have an allergic reaction, stop taking Janumet XR and call your doctor right away. Your doctor may prescribe a medication to treat your allergic reaction and a different medication for your diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas. Stop taking Janumet XR and call your doctor right away if you experience severe and persistent stomach pain, with or without vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems (sometimes requiring dialysis) and including a condition called tubulointerstitial nephritis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, which may be severe and disabling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle aches.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arm or leg pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blisters on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver problems including cholestatic, hepatocellular, and mixed hepatocellular liver injury</p><p>&nbsp;</p><p>&nbsp;</p><p>Contact your doctor immediately if you experience muscle pain, tenderness or weakness. This is because in rare occasions the muscle problems can be serious, including the breakdown of muscle fibers that can lead to kidney damage and furthermore to death. This risk may be greater in older patients (65 years and older), female gender, patients with kidney dysfunction, and patients with thyroid problems.</p><p>&nbsp;</p><p>Other side effects not listed above may also occur in some patients.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you notice side effects which are not described here, if you develop any unusual symptom, or if any known symptom continues or worsens.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Store below 30&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the la bel after EXP.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Active</em><em> </em><em>ingredients</em></p><p>Sita gliptin as sitagliptin phosphate monohydrate, metformin hydrochloride.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Janumet XR 50 m g/500 mg contains 50 mg sitagliptin as sitagliptin phosphate monohydrate and 500 mg metformin as metformin hydrochloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Janumet XR 50 m g/1000 mg contains 50 mg sitagliptin as sitagliptin phosphate monohydrate and 1000 mg metformin as metformin hydrochloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Janumet XR 100 m g/1000 mg contains 100 mg sitagliptin as sitagliptin phosphate monohydrate and 1000 mg metformin as metformin hydrochloride</p><p>&nbsp;</p><p><em>Excipients</em></p><p>Propyl gallate, polyethylene glycolthe color indigotine (E132), sodium stearyl fumarate, povidone (K29/32), purified water, , hydroxypropyl cellulose, hypromellose, colloidal silicon dioxide, macrogol 3350 , kaolin, titanium dioxide (E171) and carnauba wax. Janumet XR 50 mg/500 mg tablets contain in addition microcrystalline cellulose.</p><p>Janumet XR 50 mg/1000 mg tablets contain in addition yellow iron oxide(E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                *	Janumet XR 50 mg/500 mg is available in bottles of 56 film-coated tablets.
50 mg/500 mg tablets are light blue, bi-convex oval, film-coated tablets with “78” debossed on one side.

*	Janumet XR 50 mg/1000 mg is available in bottles of 56 film-coated tablets.
50 mg/1000 mg tablets are light green, bi-convex oval, film-coated tablets with “80” debossed on one side.

*	Janumet XR 100 mg/1000 mg is available in bottles of 28 film-coated tablets.
100 mg/1000 mg tablets are blue, bi-convex oval, film-coated tablets with “81” debossed on one side.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:</p><p>Merck Sharp &amp; Dohme Corp.,</p><p>One Merck Drive P.O. Box 100 Whitehouse Station, NJ 08889 United States</p><p>&nbsp;</p><p>Manufacturer:</p><p>MSD International GmbH (Puerto Rico Branch) LLC PRIDCO Industrial Park</p><p>State Road 183</p><p>Las Piedras, Puerto Rico 00771 U.S.A.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2019 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">قرص جانوميت إكس آر يحتوي على دوائين مختلفين، هما: سيتاجلبتين و ميتفورمين. سيتاجلبتين، ينتمي إلى فئة من الأدوية تدعى مثبطات DPP-4 (مثبطات الببتيديز ثنائي الببتيد الرابع ). ميتفورمين، ينتمي إلى فئة من الأدوية تدعى البيجيونايد.</p><p dir="RTL">حيث يعملان معًا على التحكم في مستوى سُكّر الدم لدى المرضى البالغين المصابين بمرض السُّكَّري من النوع الثاني. يساعد هذا الدواء على تحسين مستوى الإنسولين بعد الأكل و تقليل كمية السُّكَّر التي ينتجها الجسم. و يُدعى مرض السُّكَّري من النوع النوع الثاني أيضا مرض السُّكَّري غير المعتمد على الأنسولين.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">لقد وصف لك طبيبك جانوميت إكس آر للمساعدة في خفض نسبة السكر في الدم، والتي هي مرتفعة جدًّا بسبب مرض السُّكَّري من النوع الثاني ولا يمكن السيطرة عليه مع النظام الغذائي وممارسة الرياضة وحدها.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">يساعد جانوميت إكس آر على تحسين مستويات الأنسولين بعد تناول الطعام وتقليل كمية السكر التي أنتجها الجسم. يساعد جانوميت إكس آر الجسم على الاستجابة بشكل أفضل للأنسولين الذي يصنعه بشكل طبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتناول جانوميت إكس آر فقط بناءً على وصفة طبية من الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>أعرفه</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>ذلك؟</strong></p><p dir="RTL">ما السُّكّري من النوع 2؟</p><p dir="RTL">إنّ السُّكّري من النوع الثاني هو حالة معينة في الجسم&nbsp; تجعله لاينتج ما يكفي من الإنسولين، والإنسولين الذي ينتجه جسمك لا يعمل بشكل جيد أو كما يجب عمله. ويمكن أن ينتج جسمك الكثير من السكر. وعندما يحدث ذلك، يتراكم السكر في الدم. مما قد يؤدي إلى مشاكل صحية خطيرة.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">الهدف الرئيسي من علاج مرض السُّكَّري هو خفض نسبة السكر في الدم إلى مستوى طبيعي. قد يساعد خفض نسبة السكر في الدم والتحكم فيه &nbsp;من منع أو تأخير مضاعفات مرض السُّكَّري مثل أمراض القلب وأمراض الكلى والعمى والبتر. يمكن خفض نسبة السكر المرتفعة في الدم عن طريق النظام الغذائي وممارسة الرياضة، وبعض الأدوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>جانوميت إكس آر</strong><strong>:</strong></p><p>Arabic translation.&nbsp;</p><p dir="RTL">لا تتناول جانوميت إكس آر إذا كنتَ مصابًا بالحساسية من المواد الفعالة أو غير الفعالة، أو لديك النوع الأول من مرض السُّكَّري ، أو كنت تعاني من حالة طبية تسمى الحماض الأيضي أو الحماض الكيتوني السُّكَّري (زيادة الكيتونات في الدم أو البول) ، أو إذا كان لديك مشاكل حادة في وظائف الكلى. أيضا لا تتناول جانوميت إكس آر إذا كان لديك حالة طبية و التي يمكن أن تؤدي إلى مشاكل في الكلى مثل بعض أمراض القلب, أنواع معينة من العدوى الخطيرة مع على سبيل المثال ارتفاع درجة الحرارة, الإسهال و / أو القي (فقدان كبير من سوائل الجسم ) أو سوف تتعرض للحقن بصبغة أو عامل التباين لإجراء الأشعة السينية. تحدث مع طبيبك حول متى يجب إيقاف جانوميت إكس آر ومتى تبدأ من جديد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>Arabic translation.&nbsp;</p><p dir="RTL"><strong>متى</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>أكون</strong><strong> </strong><strong>حذرًا</strong><strong> </strong><strong>في</strong><strong> </strong><strong>تناول جانوميت إكس آر ؟</strong></p><p dir="RTL">أخبر طبيبك إذا كنت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتَ مصابًا بمشاكل في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتَ مصابًا بمشاكل في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتَ مصابًا بمشاكل في القلب، بما فيها بما في ذلك قصور القلب الاحتقاني (عندما لا يضخ القلب الدم بشكل كاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مفرطًا بتناول الكحول (في كل الأوقات أو الشرب بنهم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تنوين الحمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ امرأةً مُرضعًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لديك حالة قد تكون مرتبطة بالجفاف و فقدان كبير من سوائل الجس مثل القيء الشديد أو الإسهال أو الحمى، أو إذا كنت تشرب السوائل أقل بكثير من المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تخضع لعملية جراحية</p><p dir="RTL">Arabic translation.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جانوميت إكس آر </strong></p><p dir="RTL">تم الإبلاغ عن حالات التهاب البنكرياس في المرضى الذين يتناولون جانوميت إكس آر. &nbsp;يمكن أن يكون التهاب البنكرياس حالة طبية خطيرة و يحتمل أن تهدد الحياة. توقف عن تناول جانوميت إكس آر واتصل بطبيبك إذا كنت تعاني من ألم شديد ومستمر في المعدة، مع أو بدون قيء، لأنك قد تعاني من التهاب البنكرياس.</p><p dir="RTL">استشر طبيبك على الفور إذا كنت تعاني من ألم العضلات غير المبرر، أو الضعف. في حالات نادرة، يمكن أن تكون مشاكل العضلات خطيرة، بما في ذلك انهيار العضلات التي يمكن أن تؤدي إلى تلف الكلى. &nbsp;يمكن أن يكون الخطر أعلى في المرضى الذين يعانون من وظائف الكلى غير الطبيعية.</p><p dir="RTL">تم الإبلاغ عن حالات رد فعل الجلد تسمى شبيه الفقاع الفقاعي في المرضى الذين يتناولون جانوميت إكس آر و التي يمكن أن تتطلب العلاج في المستشفى</p><p dir="RTL">&nbsp;قم بزيارة الطبيب إذا كنت تصاب ببثور أو تقرحات في بشرتك . قد يقرر طبيبك أنك بحاجة إلى التوقف عن تناول جانوميت إكس آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يحتوي هذا المنتج الطبي على أقل من 1 ملليمول صوديوم) 23 ملغم) لكل قرص ، أي أنه &quot;خالي من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p><p dir="RTL"><strong>الاستحدام لدى الأطفال والمراهقين</strong></p><p dir="RTL">يجب عدم استخدام جانوميت إكس آر من الأطفال والمراهقين الذين تقل سنهم عن 18 عامًا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام</strong><strong> </strong><strong>في</strong><strong> </strong><strong>كبار</strong><strong> </strong><strong>السن</strong><strong> </strong></p><p dir="RTL">يجب استخدام جانوميت إكس آر في المرضى المسنين فقط تحت إشراف طبي منتظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إبلاغ طبيبك أو الصيدلي إذا كنت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من أمراض أخرى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية أخرى (بما في ذلك تلك بدون وصفة طبية).</p><p dir="RTL">&nbsp;</p><p>Arabic translation.&nbsp;</p><p dir="RTL"><strong>هل</strong><strong> </strong><strong>يمكنني</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جانوميت إكس آر</strong><strong> </strong><strong>أثناء</strong><strong> </strong><strong>الحمل</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الرضاعة؟</strong><strong> </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مُرضعًا ، أو تُحاولين الحمل، أو تظنّين أنّك قد تكونين حاملًا ، فإنه يجب عليكِ استشارة طبيبك أو الصيدلاني قبل تناول جانوميت إكس آر . لا ينصح بتناول جانوميت إكس آر أثناء الحمل. ومن غير المعروف ما إذا كان جانوميت إكس آر يمر في حليب الثدي. يجب عدم استخدام جانوميت إكس آر &nbsp;إذا كنت الرضاعة الطبيعية أو هناك نية للرضاعة الطبيعية. تحدثي إلى طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف</strong><strong> </strong><strong>يمكنني</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>جانوميت إكس آر &nbsp;؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تناول جانوميت إكس آر&nbsp; تمامًا حسب ارشادات طبيبك. سوف يخبرك طبيبك بعدد أقراص جانوميت إكس آر&nbsp; التي يجب تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج طبيبك إلى زيادة الجرعة للسيطرة على نسبة السكر في الدم.</p><p dir="RTL">قد يصف لك الطبيب جانوميت إكس آر&nbsp; مع سلفونيل يوريا أو الأنسولين (أدوية أخرى لخفض نسبة السكر في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول قرص واحد من جانوميت إكس آر&nbsp; مع وجبة العشاء للتقليل من فرصه اضطراب المعدة.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">إذا كنتت تناول جانوميت إكس آر&nbsp; ، قم بابتلاع قرص جانوميت إكس آر&nbsp; كاملًا. لا تمضغ أو تقطع أو تسحق الأقراص. أخبر طبيبك إذا كنت لا تستطيع ابتلاع قرص جانوميت إكس آر&nbsp; كاملا.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">قد ترى شيئًا يشبه قرص جانوميت إكس آر&nbsp; في البراز . إذا رأيت أقراصًا في البراز عدة مرات، تحدث إلى طبيبك. لا تتوقف عن تناول جانوميت إكس آر &nbsp;من غير التحدث إلى طبيبك.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">استمر في تناول جانوميت إكس آر&nbsp; طالما يصفها الطبيب حتى تتمكن من الاستمرار في المساعدة في التحكم في نسبة السكر في الدم.</p><p dir="RTL">&nbsp;</p><p>Arabic translation.&nbsp;</p><p dir="RTL">قد تحتاج إلى إيقاف جانوميت إكس آر لفترة قصيرة، اتصل بطبيبك للحصول على تعليمات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لديك حالة &nbsp;طبية قد تكون مرتبطة بالجفاف (فقدان كبير من سوائل الجسم) مثل المرضى مع القيء الشديد أو الإسهال أو الحمى، أو إذا كنت تشرب السوائل أقل بكثير من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نية لإجراء عملية جراحية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو سوف تتعرض للحقن بصبغة أو عامل التباين لإجراء الأشعة السينية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يساعد النظام الغذائي وممارسة الرياضة الجسم على استخدام سكر الدم بشكل أفضل . من المهم أن تلتزم بالنظام الغذائي الذي أوصى به الطبيب وممارسة الرياضة وبرنامج فقدان الوزن أثناء تناول جانوميت إكس آر .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت جرعة زائدة من جانوميت إكس آر ، اتصل بطبيبك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد نسيت تناول الجرعة، فتناولها حالما تتذكر. إذا لم تتذكر إلّا عند وقت الجرعة التالية، تخطَّ الجرعة الفائتة وعد إلى الجدول الزمني الخاصّ بك المعتاد. لا تتناول جرعة مضاعفة من جانوميت إكس آر&nbsp; .</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تغير جرعة جانوميت إكس آر&nbsp; الموصوفة من قبل الطبيب. تحدث إلى طبيبك أو الصيدلي إذا كنت تشعر بأن الدواء غير فعال أو قوي للغاية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">في حالات نادرة،، يمكن أن يسبب الميتفورمين، أحد المواد الفعالة في جانوميت إكس آر&nbsp; ، عرض جانبي خطير يسمى الحماض الاكتيكي. الحماض الاكتيكي هو حالة طبية طارئة يمكن أن تسبب الوفاة ويجب أن تُعالج في المستشفى. &nbsp;يحدث الحماض الاكتيكي عند تراكم حمض اللاكتيك في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناولى جانوميت إكس آر عند ظهور الأعراض</strong><strong> </strong><strong>التالية نتيجة الحماض الاكتيكي :</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بالضعف الشديد والتعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك ألم العضلات غير عادي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشكلة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك ألم في المعدة مع الغثيان والقيء، أو الإسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بالبرد، خاصة في ذراعيك وساقيك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تشعر بالدُّوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك ضربات القلب بطيئة أو غير منتظمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالتك الطبية تتغير فجأة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لديك</strong><strong> </strong><strong>فرصة</strong><strong> </strong><strong>أكبر</strong><strong> </strong><strong>لحدوث</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الحماض الاكتيكي إذا</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدبك مشاكل خطيرة في الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدبك مشاكل في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدبك قصور القلب الاحتقاني الذي يتطلب العلاج بالأدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكثير من الكحول بنهم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث جفاف و فقد كمية كبيرة من سوائل الجسم . يمكن أن يحدث هذا إذا كنت مريضًا بالحمى أو القيء أو الإسهال. يمكن أن يحدث الجفاف أيضًا عند التعرق كثيرًا مع النشاط أو التمرين ولا تشرب ما يكفي من السوائل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك بعض اختبارات الأشعة السينية مع الأصباغ عن طريق الحقن أو العوامل التباين المستخدمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إجراء عملية جراحية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك نوبة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك عدوى شديدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو السكتة الدماغية</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتشمل الأعراض الجانبية الشائعة الأخرى في المرضى الذين يتناولون جانوميت إكس آر الصداع, انخفاض نسبة السكر في الدم، وأعراض الجهاز الهضمي بما في ذلك الإسهال, الغثيان ، عسر الهضم ، انتفاخ البطن ، قيء ، طعم معدني ، ألم في المعدة ، فقدان الشهية &nbsp;أو القرحة أو التقرحات. &nbsp;في معظم الحالات تحدث هذه الأعراض الجانبية في بداية العلاج وتختفي دون توقف عن العلاج. إذا كنت تتناول الميتفورمين لفترة طويلة ،سيقوم &nbsp;طبيبك باختبار الدم بانتظام بسبب انخفاض فيتامين B12 الذي &nbsp;قد يحدث.</p><p dir="RTL">&nbsp;في حالات نادرة قد تنخفض خلايا الدم البيضاء والصفائح الدموية. قد يحدث كذلك انسداد في الأنف والتهاب الحلق ، عدوى الجهاز التنفسي العلوي ، و ارتفاع غير طبيعي في اختبارات فحص الكبد و الصداع. &nbsp;يمكن أن يساعد تناول جانوميت إكس آر مع الوجبات في تقليل مشاكل المعدة ، ومع ذلك إذا كنت تواجه مشاكل غير عادية و/ أو غير متوقعة في المعدة، تحدث مع طبيبك. قد تكون مشاكل المعدة التي تبدأ في وقت لاحق أثناء العلاج علامة على شيء أكثر خطورة.</p><p dir="RTL">عندما يتم استخدام جانوميت إكس آر مع دواء السلفونيل يوريا أو مع الأنسولين، يمكن أن يحدث انخفاض نسبة السُّكر في الدم، بسبب السلفونيل يوريا أو الأنسولين. سوف يقوم طبيبك بتقليل جرعة دواء السلفونيل يوريا أو الأنسولين. بالإضافة إلى ذلك، عندما يتم استخدام جانوميت إكس آر مع دواء السلفونيل يوريا، قد يحدث الإمساك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تم الإبلاغ عن أعراض جانبية إضافية في الاستخدام العام لجانوميت إكس آر ، &nbsp;أو سيتاجلبتين ، أحد المواد الفعالة المكونة لجانوميت إكس آر ، عندما تم استخدام جانوميت إكس آر لوحده أو مع أدوية السُّكَّري الأخرى :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية التي قد تكون خطيرة بما في ذلك الطفح الجلدي، و الشرى ، وتورم في الوجه والشفتين واللسان، والحلق التي قد تسبب صعوبة في التنفس أو البلع. &nbsp;إذا كان لديك رد فعل تحسسي، توقف عن تناول جانوميت إكس آر واتصل بطبيبك على الفور. قد يصف لك طبيبك دواءً لعلاج رد الفعل التحسسي وأدوية مختلفة لمرض السُّكَّري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس. توقف عن تناول جانوميت إكس آر واتصل بطبيبك على الفور إذا كنت تعاني من ألم شديد ومستمر في المعدة، مع أو بدون قيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى والتي تتطلب غسيل الكلى في بعض الأحيان &nbsp;بما في ذلك حالة تسمى التهاب الكلية الخلالي الأنبوبي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل والتي قد تكون شديدة ومعيقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الذراع أو الساق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور على الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكبد بما في ذلك إصابة الكبد الركودي والكبدي الخلوي والمختلط</p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت تعاني من ألم العضلات الضعف ، وذلك لأن في حالات نادرة يمكن أن تكون مشاكل العضلات خطيرة، بما في ذلك انهيار ألياف العضلات التي يمكن أن تؤدي إلى تلف الكلى وعلاوة على ذلك إلى الموت. قد يكون هذا الخطر أكبر في المرضى الأكبر سنًّا ( 65سنة فأكثر) ، و الإناث ، والمرضى الذين يعانون من خلل في الكلى ، والمرضى الذين يعانون من مشاكل الغدة الدّرقيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث آثارًا جانبية أخرى غير المذكورة أعلاه أيضًا في بعض المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا لاحظت آثارًا جانبية غير مذكورة هنا ، إذا ظهرت أي أعراض غير عادي ة، أو إذا استمرت أي أعراض معروفة أو تزداد سوءًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الابلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p dir="RTL">اتّصل بالطبيب في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء، بالمملكة&quot;. يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الابلاغ عن الأعراض الجانبيّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">يحفظ على درجة حرارة أقل 30 درجة مئوية .</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة و بعد الرمز &quot;EXP&quot;.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">يحفظ على درجة حرارة أقل 30 درجة مئوية .</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة و بعد الرمز &quot;EXP&quot;.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما المظهر الخارجي لأقراص </strong><strong>جانوميت إكس آر </strong><strong>و ما محتويات العبوة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص جانوميت 50 ملغم / 500 ملغم متوفرة بعلب من 56 قرصًا مغلفًا.</p><p dir="RTL">أقراص جانوميت 50 ملغم / 500 ملغم ، &nbsp;مغلفة ذات لون أزرق فاتح, بيضاوية ثنائية محدبة مع حفر&nbsp; &quot;78&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص جانوميت 50 ملغم / 1000 ملغم متوفرة بعلب من 56 قرصًا مغلفًا.</p><p dir="RTL">أقراص جانوميت 50 ملغم / 1000 ملغم ، &nbsp;مغلفة ذات لون أخضر فاتح ، بيضاوية ثنائية محدبة مع حفر&nbsp; &quot;80&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص جانوميت 100 ملغم / 1000 ملغم متوفرة بعلب من 28 قرصًا مغلفًا.</p><p dir="RTL">أقراص جانوميت 100 ملغم / 1000 ملغم ، &nbsp;مغلفة ذات لون أزرق ، بيضاوية ثنائية محدبة مع حفر&nbsp; &quot;81&quot; على جانب واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة<strong> </strong>المالكة</strong><strong> </strong><strong>لحقوق</strong><strong> </strong><strong>التسويق</strong><strong>:</strong></p><p dir="RTL">شركة ميرك شارب ودوم ،</p><p dir="RTL">وان ميرك درايف، ص.ب ١٠٠، وايت هوس ستاشن،</p><p dir="RTL">ان جيه ٠٨٨٨٩ الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>الصانعة</strong><strong>:</strong></p><p>Arabic translation.&nbsp;</p><p dir="RTL">ميرك شارب ودوم &nbsp;الدولية ( جي إم بي إتش ) فرع بورتوريكو ذ م م</p><p dir="RTL">حديقة بريدكو الصناعية</p><p dir="RTL">&nbsp;طريق الدولة 183</p><p dir="RTL">&nbsp;لاس بيدراس, بورتوريكو 00771</p><p dir="RTL">الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janumet® XR extended-release Tablets
50 mg/500 mg, 50mg/1000mg & 100mg/1000mg Sitagliptin and metformin hydrochloride

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 50 mg/500 mg film-coated tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 500 mg of metformin hydrochloride.

Each 50 mg/1000 mg film-coated tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 1000 mg of metformin hydrochloride.

Each 100 mg/1000 mg film-coated tablet contains sitagliptin phosphate monohydrate equivalent to 100 mg of sita gliptin and 1000 mg of metformin hydrochloride.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Extended-releasetablet(modified-release), contains 50 mg sitagliptin as sitagliptin phosphate monohydrate and 500 mg metformin hydrochloride extended-release (Janumet XR 50 mg/500 mg), or 1000 mg metformin hydrochloride extended-release (Janumet XR 50 mg/1000 mg) or 100 mg sitagliptin as sitagliptin phosphate monohydrate and 1000 mg metformin hydrochloride extended-release (Janumet XR 100 mg/1000 mg).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Janumet XR is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Janumet XR is a lso indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in pa tients with type 2 dia betes mellitus ina dequately controlled with any two of the three agents: metformin, sita gliptin, or a sulfonylurea.</p><p>&nbsp;</p><p>If the blood glucose level is insufficiently controlled by diet and exercise and insulin- in combination with insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The dosage of antihyperglycemic therapy with Janumet XR should be individualized on the basis of the patient&rsquo;s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.</p><p>&nbsp;</p><p>Janumet XR should be given once daily with a meal preferably in the evening.</p><p>The dose should be escalated gradually to reduce the gastrointestinal (GI) side effects due to metformin. To preserve the modified-release properties, the tablets must not be split, broken, crushed, or chewed before swa llowing.</p><p>The plasma concentrations of metformin are enhanced by administration of Janumet XR with food. There have been reports of incompletely dissolved Janumet XR tablets being eliminated in the feces. It is not known whether this material seen in feces contains active drug. Therefore, glycemic control should be carefully a ssessed in patients reporting repeatedly seeing remainders of tablets in feces.</p><p>Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring</p><p>because of potential changes in glycaemic control. The same also applies when switching from metformin tablets without extended release to extended-release metformin, e.g., Janumet XR.</p><p>&nbsp;</p><p><em>Dosing Recommendations:</em></p><p>The starting dose of Janumet XR should be based on the patient&rsquo;s current regimen.</p><p>&nbsp;</p><p>Janumet XR should be given once daily with a meal preferably in the evening. Janumet XR tablets are availa ble in the following strengths:</p><p>&nbsp;</p><p>50 mg sita gliptin/500 mg extended-release metformin hydrochloride 50 mg sita gliptin/1000 mg extended-release metformin hydrochloride 100 mg sita gliptin/1000 mg extended-release metformin hydrochloride</p><p>&nbsp;</p><p>For patients using the 50 mg sita gliptin/500 mg metformin hydrochloride extended-release tablet or the 50 mg sita gliptin/1000 mg metformin hydrochloride extended-release tablet, two tablets should be taken together once daily. The 100 mg sita gliptin/1000 mg metformin hydrochloride extended-release tablet should be taken as a single tablet once daily.</p><p>&nbsp;</p><p><em>For patients inadequately controlled on metformin monotherapy:</em></p><p>For patients inadequately controlled on metformin alone, the recommended total daily starting dose of Janumet XR is 100 mg sitagliptin and the previously prescribed dose of metformin.</p><p>&nbsp;</p><p><em>For patients inadequately controlled on sitagliptin monotherapy:</em></p><p>For patients inadequately controlled on sitagliptin alone, the recommended total daily starting dose of Janumet XR is 100 mg sita gliptin and 1000 mg metformin hydrochloride. The metformin dose can be titrated as needed to achieve glycemic control. Gradual dose escalation to reduce the gastrointestinal (GI) side effectsassociated with metformin should be considered. Patientstaking sitagliptin monotherapy dose- adjusted for renal impairment should not be switched to Janumet XR (see <strong>CONTRAINDICATIONS)</strong>.</p><p>&nbsp;</p><p><em>For patients switching from coadministration of sitagliptin and metformin:</em></p><p>For patients switching from coadministration of sita gliptin and metformin, Janumet XR may be initiated at the dose of sitagliptin and metformin already being taken.</p><p>&nbsp;</p><p><em>For patients inadequately controlled on dual combination therapy with any two of the following three antihyperglycemicagents: sitagliptin, metformin or a sulfonylurea:</em></p><p>The usual starting dose of Janumet XR should provide 100 mg total daily dose of sitagliptin. In determining the starting dose of the metformin component, the patient&rsquo;s level of glycemic control and current dose (if any) of metformin should be considered. Gradual dose escalation to reduce the gastrointestinal (GI) side effects associated with metformin should be considered. Pa tients currently on or initia ting a sulfonylurea may require lower sulfonylurea doses to reduce the risk of sulfonylurea-induced hypoglycemia (see <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><em>For patients inadequately controlled on dual combination therapy with any two of the following three antihyperglycemicagents: sitagliptin, metformin or insulin:</em></p><p>The usual starting dose of Janumet XR should provide 100 mg total daily dose of sitagliptin. In determining</p><p>the starting dose of the metformin component, the patient&rsquo;s level of glycemic control and current dose (if any) of metformin should be considered. Gradual dose escalation to reduce the gastrointestinal (GI) side effects associated with metformin should be considered. Pa tients currently on or initia ting insulin therapy may require lower doses of insulin to reduce the risk of hypoglycemia (see <strong>PRECAUTIONS</strong>).</p><p>&nbsp;</p><p>No studies have been performed specifically examining the safety and efficacy of Janumet XR in patients previously treated with other oral antihyperglycemic a gents and switched to Janumet XR. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><em>Recommendations for use in renal impairment:</em></p><p>Assess renal function prior to initiation of Janumet XR and periodically thereafter.</p><p>&nbsp;</p><p>Janumet XR is contraindicated in patients with an estima ted glomerular filtra tion rate (eGFR)</p><p>&lt; 30 mL/min/1.73 m<sup>2</sup>. Discontinue Janumet XR if the patient&rsquo;s eGFR la ter falls below 30 mL/min/1.73 m<sup>2</sup> (see <strong>CONTRAINDICATIONS </strong>and <strong>SPECIAL WARNINGS AND PRECAUTIONS FOR USE</strong>).</p><p>&nbsp;</p><p>Initia tion of Janumet XR in patients with an eGFR &ge; 30 mL/min/1.73 m<sup>2</sup> and &lt; 45 mL/min/1.73 m<sup>2</sup> is not recommended. In patients taking Ja numet XR whose eGFR la ter falls below 45 mL/min/1.73 m<sup>2</sup>, a ssess the benefit and risk of continuing therapy and limit dose of the sitagliptin component to 50 mg once day.</p><p>&nbsp;</p><p><em>Use in children and adolescents</em></p><p>Safety and effectiveness of Ja numet XR in children and adolescent patients have not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Use in the elderly</em></p><p>As metformin and sitagliptin are substantially excreted by the kidney, Janumet XR should be used with caution as age increases. Monitoring of renal function is necessary to aid in prevention of metformin- associated la ctic acidosis, particularly in the elderly (see <strong>SPECIAL WARNINGS AND PRECAUTIONS </strong><strong>FOR USE, </strong><em>Metformin hydrochloride</em>, Lactic acidosis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janumet XR is contraindicated in pa tients with:

1.	Severe renal impairment (eGFR < 30 mL/min/1.73 m2) (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride, Renal Impairment).
2.	Acute diseases that might lead to a renal impa irment, e.g. cardiovascular compromise (including myocardial infa rction), sepsis, dehydration (dia rrhea, repeated vomiting), severe infections, for example of the urinary tract, high fever.
3.	Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of Janumet XR (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Sitagliptin phosphate, Hypersensitivity Reactions and SIDE EFFECTS, Postmarketing Experience).
4.	Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
5.	Intravascular applica tion of iodine-containing contrast agents for radiological investigations may lead to kidney failure and in consequence may cause accumulation of metformin and lactic acidosis. Treatment with metformin must be stopped 48 hours before any such investigation, if creatinine clea rance is <60 ml/min or eGFR is <60 ml/min/1.73 m2. Therapy with metformin may only be continued if renal function has been checked 48 hours after the investigation involving a contrast agent and there has been no further deterioration (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Janumet XR should be temporarily discontinued in patients being administered intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE; Metformin hydrochloride).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Janumet XR</p><p>Janumet XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. <u>Pancreatitis</u></p><p>There have been reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis (see SIDE EFFECTS), in patients taking sita gliptin. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pa in. Resolution of pancreatitis has been observed after discontinuation of sitagliptin. If pancreatitis is suspected, Ja numet XR, and other potentially suspect medicinal products should be discontinued.</p><p>&nbsp;</p><p><u>Monitoring of Renal Function</u>: Metformin and sitagliptin are known to be substantially excreted by the kidney. Before initia tion of therapy with Janumet XR renal function should be a ssessed as the risk of metformin accumulation and lactic acidosis increases with increa sing impairment of renal function. Janumet XR is contraindicated in pa tients with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m<sup>2</sup>).</p><p>&nbsp;</p><p>Renal function should be re-a ssessed under treatment with Janumet XR at regula r intervals, at lea st:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; annually in patients with normal renal function;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least every 3 &ndash; 6 months in patients with an eGFR of &ge;45 &ndash; 59 ml/min/1.73 m<sup>2</sup>, as well as in elderly patients;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least every 3 months in patients with an eGFR of &ge;30 &ndash; 44 ml/min/1.73 m<sup>2</sup>.</p><p>Janumet XR should be discontinued immediately, if eGFR fa lls below 30 ml/min/1.73 m<sup>2</sup>.</p><p><u>Use with Medications Known to Cause Hypoglycemia</u>: It is known that antidiabetic medication of the sulfonylurea type or insulins can cause hypoglycemia. Therefore, a reduction of the sulfonylurea or insulin dose, respectively may be necessary when taking these substances in combination with Janumet XR.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Sitagliptin phosphate Myopathy / Rhabdomyolysis</em></p><p>Myopathies have been reported in connection with the use of Janumet, which manifest in the form of muscle pain, weakness or tenderness together with highly increased creatine kinase (CK, to ten times the upper limit of the norm). Myopathy can sometimes occur in the form of rhabdomyolysis with or without acute renal failure due to myoglobinuria, and deaths have rarely occurred.</p><p>&nbsp;</p><p>Physiciansshould prescribe Janumet with caution in patients with predisposing factors for rhabdomyolysis. A creatine kinase level should be determined before starting treatment in the following situations:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairment of kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-controlled hypothyroidism</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal or family history of hereditary muscle disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; History of muscle toxicity with a statin or fibrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol addiction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly persons (&ge; 65 years): the necessity of such measurement should be considered in the presence</p><p>of other predisposing factors for rhabdomyolysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Female gender: the necessity of such measurement should be considered in the presence of other predisposing factors for rhabdomyolysis</p><p>&nbsp;</p><p>In these situations, the risk of treatment should be considered in relation to the possible benefits.</p><p><u>Use with Medications Known to Cause Hypoglycemia</u>: In clinical tria ls of sita gliptin as monotherapy and as part of combination therapy with agents not known to cause hypoglycemia (i.e., metformin or PPAR&gamma; agonists (thia zolidinedione)), rates of hypoglycemia reported with sitagliptin were similar to rates in patients taking pla cebo.</p><p>&nbsp;</p><p><em>Hypersensitivity Reactions:</em></p><p>There have been postmarketing reports of serious hypersensitivity reactions in patients treated with sitagliptin, one of the components of Janumet XR. These reactions include anaphylaxis, angioedema, and exfolia tive skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initia tion of treatment with sitagliptin, with some reports even occurring after the first dose. Because these reactions are reported from a population of uncertain size, it is not possible to reliably estimate their frequency. If a hypersensitivity reaction is suspected, discontinue Janumet XR. (See <strong>CONTRAINDICATIONS </strong>and <strong>SIDE EFFECTS</strong>, <em>Postmarketing Experience</em>.)</p><p>&nbsp;</p><p><em>Bullous Pemphigoid:</em></p><p>Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered under topical or systemic immunosuppressive treatment and following discontinuation of the DPP-4 inhibitor. Tell patients to contact their doctor upon development of blisters or erosions of the skin while under trea tment with Janumet XR. If bullous pemphigoid is suspected, Ja numet XR should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Lactic Acidosis: Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with Janumet XR (<em>sitagliptin phosphate/metformin HCl extended-release</em>); when it occurs, it is fa tal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including dia betes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is cha racterized by elevated blood lactate levels (&gt;5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated asthe cause of lactic acidosis, metformin plasma levels &gt;5 &micro;g/mL are generally found.</p><p>&nbsp;</p><p>The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1&rsquo;000 patient-years, with approximately 0.015 fatal cases/1&rsquo;000 patient-years). In more than 20&rsquo;000 patient-years exposure to metformin in clinica l tria ls, there were no reports of la ctic acidosis. Reported cases have occurred primarily in diabetic patients with severe impairment of renal function or chronic renal failure. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure with hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal insufficiency and the patient&#39;s age. The risk of la ctic acidosis may, therefore, be significa ntly decreased by regular monitoring of renal function in patients taking metformin and by use of the minimum effective dose of metformin. In particular, treatment of the elderly should be accompanied by ca reful monitoring of renal function (see <em>Use in the elderly</em>, <em>Metformin hydrochloride</em>). In addition, metformin should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clea r la ctate, metformin should generally be avoided in patients with clinical or la boratory evidence of hepatic disease.</p><p>Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking metformin, since alcohol potentiates the effects of metformin hydrochloride on la cta te metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular ra diocontrast a pplication and for any surgical procedure.</p><p>&nbsp;</p><p>The onset of lactic acidosis often is subtle, and accompanied primarily by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, a nd resistant bradyarrhythmias with more marked acidosis. The patient and the patient&#39;s physician must be aware of the possible importance of such symptomsand the patient should be instructed to notify the physician immediately if they occur. Metformin should be</p><p>&nbsp;</p><p>withdra wn and the patient should be hospitalized. Serum electrolytes, ketones, blood glucose, and blood pH, lactate levels, and even blood metformin levels may be useful.</p><p>&nbsp;</p><p>Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending la ctic acidosis a nd may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling.</p><p>&nbsp;</p><p>Lactic acidosis should be suspected in any diabetic pa tient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).</p><p>&nbsp;</p><p>Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride and lactate are dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended. Such management often resultsin prompt reversal of symptoms and recovery (see <strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p>Once a pa tient is stabilized on any dose level of metformin, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.</p><p>&nbsp;</p><p><u>Hypoglycemia:</u> Hypoglycemia doesnot occur in patientsreceiving metformin as monotherapy under usual circumstances of use, but could occur in exceptions for example when ca loric intake is deficient, with strenuous exercise, or during concomitant use with alcohol or other glucose-lowering agents (such as sulfonylureas and insulin).</p><p>Elderly, debilita ted, or ma lnourished patients, and those with adrenal or pituitary insufficiency or a lcohol</p><p>intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to</p><p>recognize in the elderly, and in people who are taking &beta;-adrenergic blocking drugs.</p><p>&nbsp;</p><p><u>Use of concomitant medications that may affect renal function or metformin disposition:</u> Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see <strong>DRUG INTERACTIONS</strong>, <em>Metformin hydrochloride</em>), should be used with caution.</p><p>&nbsp;</p><p><em>Application of iodine-containing contrast agents</em></p><p>Intravascular application of iodine-containing contrast agents for radiological investigations may lead to rena l failure. As this can cause accumulation of metformin and la ctic acidosis, treatment with metformin must be stopped timely (about 2 days) before any such investigation in patients with an eGFR of &lt;60 ml/min/1.73 m<sup>2</sup>. Therapy with metformin may only be resumed if renal function has not deteriorated 2 days after the investiga tion involving a contrast agent.</p><p><u>Hypoxic states:</u> Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute</p><p>myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on Janumet XR therapy, the drug should be promptly discontinued.</p><p>&nbsp;</p><p><u>Surgical procedures:</u> Use of Janumet XR should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should only be resta rted when the patient&#39;s oral intake has resumed and renal function has been evaluated as acceptable (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><u>Alcohol intake:</u> Alcohol is known to potentiate the effect of metformin on la ctate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving Janumet XR.</p><p>&nbsp;</p><p><u>Sodium:</u> This medicinal product contains less than 1 mmol sodium (23 mg) per tablet and is considered to be essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Impaired hepatic function:</u> Since impaired hepatic function has been associated with some cases of lactic acidosis, Janumet XR should generally be avoided in patients with clinical or laboratory evidence of hepatic disea se.</p><p>&nbsp;</p><p><u>Vitamin B</u><u>12 levels:</u>&nbsp;In controlled clinica l tria ls of metformin of 29 weeksduration, a decrease to subnormal levels of previously normal serum Vitamin B12 levels, without clinica l manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to the reduction of the B12 absorption, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12 supplementation. Measurement of&nbsp;hematologic parameters on an annual basis is advised in patients on Janumet XR and a ny apparent abnormalities should be a ppropriately investigated and managed.</p><p>&nbsp;</p><p>Certain individuals (those with inadequate Vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal Vitamin B12 levels. In these patients, routine serum Vitamin B12 measurements at two- to three-year intervals may be useful.</p><p>&nbsp;</p><p><u>Change in clinical status of patients with previously controlled type 2 diabetes:</u> A patient with type 2 diabetes previously well controlled on Janumet XR who develops la boratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If a metabolic acidosis is suspected &ndash; irrespective of its genesis - Janumet XR must be stopped immediately a nd the patient be hospitalized.</p><p>&nbsp;</p><p><u>Loss of control of blood glucose:</u> When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold Janumet XR and temporarily administer insulin. Janumet XR may be reinstituted after the acute episode is resolved.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Use in children and adolescents</em></p><p>Safety and effectiveness of Janumet XR and one of its components, sita gliptin in children and adolescent patients under 18 years have not been established.</p><p>&nbsp;</p><p><em>Use in the elderly</em></p><p>Janumet <em>XR</em></p><p><em>&nbsp;</em></p><p>As metformin and sitagliptin are substantially excreted by the kidney, Janumet XR should be used with caution as age increases. Monitoring of renal function is necessary to aid in prevention of metformin- associated la ctic acidosis, particularly in the elderly (see <strong>SPECIAL WARNINGS AND PRECAUTIONS </strong><strong>FOR USE, </strong><em>Metformin hydrochloride</em>, Lactic acidosis).</p><p>&nbsp;</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>In clinica l studies, the safety and effectiveness of sitagliptin in the elderly (&sup3;65 years,) were comparable to those seen in younger patients (&lt;65 years).</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Controlled clinica l studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p><p>&nbsp;</p><p>Genera lly, Janumet t XR should be taken together with the evening meal. By administration together with food the gastrointestinal side effects of metformin can partially be reduced. In addition it has to be anticipated that the bioavaila bility of extended-release metformin is reduced when administered on an empty stomach. This could make diabetic control more difficult. It has to be considered that the bioavailability of metformin without extended release is reduced by concomitant food administration - in contrast to extended-release metformin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Sitagliptin and metformin</em></p><p>Coadministration of multiple doses of sitagliptin (50 mg b.i.d.) and metformin (1000 mg b.i.d.) did not meaningfully a lter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 dia betes.</p><p>&nbsp;</p><p>Pharmacokinetic drug interaction studies with Janumet XR have not been performed; however, such studies have been conducted with the individual components of Janumet XR, sita gliptin and metformin.</p><p>&nbsp;</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>In drug interaction studies, sitagliptin did not have clinically meaningful effects on the pharmacokinetics of the following: metformin, rosiglita zone, glyburide, simvastatin, warfarin, and oral contraceptives. Based on these data, sita gliptin does not inhibit CYP isozymes CYP3A4, 2C8, or 2C9. Based on <em>in vitro </em>data, sitagliptin is also not expected to inhibit CYP2D6, 1A2, 2C19 or 2B6 or to induce CYP3A4.</p><p>&nbsp;</p><p>Population pharmacokinetic analyses have been conducted in patients with type 2 diabetes. Concomitant medications did not have a clinica lly meaningful effect on sita gliptin pharmacokinetics. Medications assessed were those that are commonly administered to patients with type 2 diabetes.</p><p>&nbsp;</p><p>There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax,&nbsp;18%)&nbsp;of&nbsp;digoxin with the coadministration of sitagliptin. These increases are not considered to be clinica lly meaningful. Patients receiving digoxin should be monitored appropriately.</p><p>The AUC and Cmax of sitagliptin were increased approximately&nbsp;29% and 68%, respectively, in subjects with coadministration of a single 100-mg oral dose of sita gliptin and a single 600-mg oral dose of cyclosporine, a potent probe inhibitor of p-glycoprotein. The observed changes in sita gliptin pharmacokinetics are not considered to be clinically meaningful.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p><u>Glyburide:</u> In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects make the clinica l significa nce of this interaction uncertain.</p><p>&nbsp;</p><p><u>Furosemide:</u>A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood AUC by 15%, without any significant change in metformin renal clea rance. When administered with metformin, the Cmax and AUC of&nbsp;furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is availa ble about the interaction of metformin and furosemide when coadministered chronically.</p><p>&nbsp;</p><p><u>Nifedipine:</u> A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma&nbsp;metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.</p><p>&nbsp;</p><p>Concomitant use of drugs that interfere with the renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure of metformin and may increase the risk for la ctic acidosis. In interaction studies with both single and multiple dose of metformin in combination with cimetidine in healthy subjects peak metformin plasma and whole blood concentrations increased by 60% and the plasma and whole blood metformin AUC increased by 40%. Therefore, consider the benefits and risks of concomitant use of these substances with metformin.</p><p>&nbsp;</p><p><u>Other:</u> Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isonia zid. When such drugs are administered to a patient receiving Janumet XR the patient should be closely observed to maintain adequate glycemic control.</p><p>&nbsp;</p><p>In healthy volunteers, the pharmacokinetics of metformin and propranolol, a nd metformin and ibuprofen were not affected when coadministered in single-dose interaction studies.</p><p>&nbsp;</p><p>Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, a nd probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>Anima l data do not suggest an effect of treatment with sitagliptin on male and female fertility. Human data are la cking.</p><p>&nbsp;</p><p>Pregnancy</p><p>There are no adequate and well-controlled studies in pregnant women with Janumet XR or its individual components; therefore, the safety of Janumet XR in pregnant women is not known. Janumet XR, like other oral antihyperglycemic agents, is not recommended for use in pregnancy.</p><p>&nbsp;</p><p>Lactation</p><p>No studies in lactating animals have been conducted with the combined components of Janumet XR. In studies performed with the individual components, both sitagliptin and metformin are secreted in the milk of lactating rats. It is not known whether sitagliptin is excreted in human milk. Therefore, Janumet XR should not be used by a woman who is nursing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:8.65pt">No studies of the effects of Janumet XR on the ability to drive and use machines have been performed. However, Janumet XR is not expected to affect the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>There were no clinical studies conducted with Janumet XR tablets. However, bioequivalence was shown between Janumet XR and sitagliptin coadministered with extended-release metformin (see <strong>PHARMACOKINETICS</strong>).</p><p>In placebo-controlled clinical tria ls, in patients with type 2 diabetes mellitus, the combination of sitagliptin</p><p>and metformin without extended release wasgenerally well tolerated. The overall incidence of side effects reported in patients receiving the combination of sitagliptin and metformin was similar to that reported in patients receiving the combination of placebo and metformin.</p><p>&nbsp;</p><p>The frequencies are defined as: common &sup3;1/100, &lt;1/10; uncommon &sup3;1/1000, &lt;1/100; rare &sup3;1/10000,</p><p>&lt;1/1000; very rare &lt;1/10000.</p><p>&nbsp;</p><p>Combination Therapy with Sitagliptin and Metformin</p><p><strong><em>&nbsp;</em></strong></p><p>In a 24-week placebo-controlled study, patients inadequately controlled with diet and exercise alone received sita gliptin 50 mg twice da ily in combination with metformin at 500 or 1000 mg twice da ily. The</p><p>&nbsp;</p><p>drug-related adverse reactions reported in &sup3;1% of patients receiving combination therapy (and greater than in patients receiving placebo) are shown as follows:</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Common: hypoglycemia</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Common: headache</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Common: diarrhea, nausea, dyspepsia, flatulence, vomiting</p><p>&nbsp;</p><p>&nbsp;</p><p>In a 24-week placebo-controlled study of sita gliptin added to ongoing metformin therapy, 464 patients on metformin were treated with sitagliptin 100 mg once daily and 237 patients were given placebo with metformin. The drug-related adverse reaction reported that occurred with an incidence of &sup3;1% and higher than placebo in patientsreceiving sitagliptin and metformin is as follows:</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Common: nausea</p><p>&nbsp;</p><p>Hypoglycemia and Gastrointestinal Adverse Experiences</p><p><strong><em>&nbsp;</em></strong></p><p>In the placebo-controlled studies of combination therapy with sitagliptin and metformin, the incidence of hypoglycemia (regardless of investigator assessment of causality) reported in patients treated with the combination of sitagliptin and metformin was similar to that reported for patients treated with metformin and placebo. The incidences of gastrointestinal adverse experiences in patientstreated with the combination of sitagliptin and metformin were simila r to those reported for pa tients treated with metformin a lone. See Table 1.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table</strong><strong> </strong><strong>1</strong></p><p><strong>Hypoglycemia and Pre-specified Gastrointestinal Intestinal Adverse Experiences (Regardless of Investigator</strong></p><p><strong>Assessment of</strong><strong> </strong><strong>Causality) Reported in Patients</strong><strong> </strong><strong>Receiving</strong><strong> </strong><strong>Combination Therapy</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>Number</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Patients (%)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Study of Sitagliptin and Metformin in patients ina dequately</p><p>controlled on diet and exercise alone</p></td><td colspan="2" style="vertical-align:top"><p><strong>Study of Sitagliptin as Add-on to</strong></p><p><strong>Metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Sitagliptin </strong><strong>100</strong><strong> </strong><strong>mg</strong><strong> </strong><strong>q.d.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Metformin</strong></p><p><strong>500</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</strong></p><p><strong>1000</strong><strong> </strong><strong>mg</strong></p><p><strong>b.i.d. </strong><sup>&dagger;&dagger;</sup></p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>50 mg b.i.d. + Metformin</strong></p><p><strong>500&nbsp; or&nbsp; 1000 mg</strong></p><p><strong>b.i.d. </strong><sup>&dagger;&dagger;</sup></p></td><td style="vertical-align:top"><p><strong>Placebo and Metformin</strong></p><p><strong>&sup3;</strong><strong>1500</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg daily</strong></p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>100</strong><strong> </strong><strong>mg</strong></p><p><strong>q.d.</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</strong></p><p><strong>Metformin</strong></p><p><strong>&sup3;</strong><strong>1500 mg</strong><strong> </strong><strong>daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N = 176</strong></p></td><td style="vertical-align:top"><p><strong>N = 179</strong></p></td><td style="vertical-align:top"><p><strong>N = 364</strong></p></td><td style="vertical-align:top"><p><strong>N = 372</strong></p></td><td style="vertical-align:top"><p><strong>N= </strong><strong>237</strong></p></td><td style="vertical-align:top"><p><strong>N= </strong><strong>464</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycemia</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>3 (0.8)</p></td><td style="vertical-align:top"><p>6 (1.6)</p></td><td style="vertical-align:top"><p>5 (2.1)</p></td><td style="vertical-align:top"><p>6 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Dia rrhea</p></td><td style="vertical-align:top"><p>7 (4.0)</p></td><td style="vertical-align:top"><p>5 (2.8)</p></td><td style="vertical-align:top"><p>28 (7.7)</p></td><td style="vertical-align:top"><p>28 (7.5)</p></td><td style="vertical-align:top"><p>6 (2.5)</p></td><td style="vertical-align:top"><p>11 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p>Na usea</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>20 (5.5)</p></td><td style="vertical-align:top"><p>18 (4.8)</p></td><td style="vertical-align:top"><p>2 (0.8)</p></td><td style="vertical-align:top"><p>6 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>2 (0.5)</p></td><td style="vertical-align:top"><p>8 (2.1)</p></td><td style="vertical-align:top"><p>2 (0.8)</p></td><td style="vertical-align:top"><p>5 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pa in<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>4 (2.3)</p></td><td style="vertical-align:top"><p>6 (3.4)</p></td><td style="vertical-align:top"><p>14 (3.8)</p></td><td style="vertical-align:top"><p>11( 3.0)</p></td><td style="vertical-align:top"><p>9 (3.8)</p></td><td style="vertical-align:top"><p>10 (2.2)</p></td></tr></tbody></table><p><sup>&dagger;</sup> Abdominal discomfort wasincluded in the analysis of abdominal pain in the study of patients inadequately controlled on diet and exercise alone</p><p><sup>&dagger;&dagger;</sup> Data pooled for the patients given the lower and higher doses of metformin.</p><p>&nbsp;</p><p>In all studies all adverse experiences of hypoglycemia were considered, including those not documented by a glucose measurement.</p><p>&nbsp;</p><p>Sitagliptin in Combination with Metformin and a Sulfonylurea</p><p>&nbsp;</p><p>In a 24-week placebo-controlled study of sitagliptin 100 mg daily added to ongoing combination treatment with glimepiride &ge;4 mg daily and metformin &ge;1500 mg daily, the drug-related adverse reactions reported in &sup3;1% of patients trea ted with sita gliptin (N=116) and more commonly than in patients treated with placebo (N=113) are shown as follows:</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Common: hypoglycemia</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Common: constipation</p><p>&nbsp;</p><p>No clinica lly meaningful changes in vita l signs or in ECG (including in QTc interval) were observed with sita gliptin plus metformin treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>Sitagliptin in Combination with Metformin and Insulin</p><p><strong><em>&nbsp;</em></strong></p><p>In a 24-week placebo-controlled study of sitagliptin 100 mg added to ongoing combination treatment with metformin &ge;1500 mg daily and stable-dose insulin, the only adverse reaction reported in &sup3;1% of patients treated with sitagliptin (N=229) a nd more commonly than in patients treated with placebo (N=233) was hypoglycemia (sitagliptin, 15.3%; placebo, 8.2%). These frequencies include all adverse events independently from the investigator assessment for causality. Especially for the rates of hypoglycemia it should be considered that all patients receiving either sitagliptin or placebo were also treated with insulin and partially with metformin. In another 24-week study of patients receiving sita gliptin as add-on therapy while undergoing insulin intensification (with or without metformin), the adverse reactions reported in &sup3;1% in patients treated with sitagliptin and metformin (N=285) and more commonly than in patients treated with placebo and metformin (N=283) were: constipation (sitagliptin and metformin, 1.4%; placebo and metformin, 1.1%), diarrhea (4.9%, 2.5%), vomiting (3.2%, 1.1%), peripheral edema (2.1%, 1.4%), pyrexia</p><p>(1.1%, 0.4%), bronchitis (1.4%, 1.1%), cellulitis (1.4%, 1.1%), pharyngitis (1.8%, 1.1%), upper respiratory</p><p>tract infection (4.2%, 1.4%), decreased creatinine clearance (1.1%, 0.0%), musculoskeletal pain (1.4%,</p><p>1.1%), myalgia (1.1%, 0.7%), nephrolithiasis (1.1%, 0.4%), and cough (2.8%, 1.8%). These frequencies include all adverse events independently from the investigator assessment for causality. Additionally, the incidence of hypoglycemia was 24.9% for patients treated with sitagliptin, metformin, and insulin and 37.8% for patients treated with placebo, metformin and insulin.</p><p>&nbsp;</p><p>Established Adverse Reactions with Sitagliptin</p><p>There were no drug-related adverse reactions reported that occurred with an incidence of &sup3;1% in patients receiving sita gliptin.</p><p>&nbsp;</p><p>Established Adverse Reactions with Metformin</p><p><em>Blood and the lymphatic system disorders</em></p><p>rare cases of leucopenia, thrombopenia and hemolytic anemia Very rare: decreased vitamin B12 levels</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Very rare: lactacidosis (incidence 3cases/100&#39;000 patient years, see Precautions)</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p>Common: mettalic taste (3%)</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Common: Gastrointestinal disorders like vomiting, nausea, diarrhea, abdominal pain, loss of appetite. These symptooms occur at the beginning of the therape a nd disappear spontaneously.</p><p>&nbsp;</p><p><em>Hepato-biliary disorders</em></p><p>Single cases: abnormal liver function tests, e.g. increased transaminases and hepatitis (reversible after discontinuation of therapy)</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>&nbsp;</p><p>Very rare: skin reactions like erythema, pruritus, urticaria.</p><p>&nbsp;</p><p>TECOS Cardiovascular Safety Study</p><p><strong><em>&nbsp;</em></strong></p><p>The Tria l Eva luating Cardiovascular Outcomes with Sita gliptin (TECOS) included 7,332 patients treated with sita gliptin, 100 mg daily (or 50 mg daily if the baseline estimated glomerular filtration rate (eGFR) was &ge;30 and &lt;50 mL/min/1.73 m<sup>2</sup>), and 7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care. The study population included a total of 2,004 patients &ge;75 years of age (970 treated with sitagliptin and 1,034 treated with placebo). The overa <strong>l </strong>incidence of serious adverse events in patients receiving sitagliptin was simila r to that in pa tients receiving placebo. Assessment of pre-specified diabetes-related complications revealed similar incidences between groups including infections (18.4% of the sita gliptin-treated patients and 17.7% of the placebo-treated patients) and renal failure (1.4% of sitagliptin-treated patients and 1.5% of placebo-treated patients). The adverse event profile in patients &ge;75 years of age was generally similar to the overall population.</p><p>&nbsp;</p><p>Among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycemia was 2.7% in sitagliptin-treated patients and 2.5% in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycemia was 1.0% in sita gliptin-treated patients and 0.7% in placebo-treated patients. The incidence of pancreatitis, confirmed by an adjudication committee, was 0.3% in sita gliptin-treated patients and 0.2% in placebo- treated patients. The incidence of malignancies, confirmed by an adjudication committee, was 3.7% in sita gliptin-treated patients and 4.0% in placebo-treated patients.</p><p>&nbsp;</p><p>Pancreatitis</p><p>In a pooled analysis of 19 double-blind clinica l tria ls that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of acute pancreatitis was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sita gliptin and 4 patients with an event in 3942 patient-years for control). (See a lso <em>TECOS Cardiovascular Safety Study </em>and <strong>WARNINGS AND PRECAUTIONS FOR USE</strong>, <em>Pancreatitis</em>).</p><p>&nbsp;</p><p>Post marketing Experience:</p><p><strong><em>&nbsp;</em></strong></p><p>Additional adverse reactions have been identified during post marketing use of Janumet XR or sitagliptin, one of the components of Janumet XR. These reactions have been reported when Janumet XR or sitagliptin have been used alone and/or in combination with other antihyperglycemic agents. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><p>Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis and exfoliative skin conditions including Stevens-Johnson syndrome (see <strong>CONTRAINDICATIONS </strong>and <strong>SPECIAL WARNINGS AND PRECAUTIONS FOR USE</strong>, <em>Sitagliptin phosphate</em>, <u>Hypersensitivity</u> <u>Reactions</u>) hepatic enzyme elevations; acute pancreatitis including fatal and non-fatal hemorrhagic and necrotizing pancreatitis (see <strong>SPECIAL WARNINGS AND PRECAUTIONS FOR USE</strong>); worsening renal function, including acute renal failure (sometimes requiring dialysis) and tubulointerstitial nephritis; mouth ulceration; stomatitis; cholestatic, hepatocellular, and mixed hepatocellular liver injury, rhabdomyolysis; bullous pemphigoid (see <strong>SPECIAL WARNINGS AND PRECAUTIONS FOR USE</strong>, <em>Bullous Pemphigoid</em>); upper respiratory tract infection; nasopharyngitis; constipation; vomiting; headache; severe and disabling arthralgia; myalgia ; pain in extremity; back pain; pruritus.</p><p>&nbsp;</p><p>&nbsp;</p><p>Laboratory test findings</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>The incidence of laboratory adverse experiences was similar in patients treated with sitagliptin and metformin compared to patients treated with placebo and metformin. Across clinica l studies, a sma <strong>l </strong>increase in white blood cell count (approximately 200 cells/microL difference in WBC vs. placebo; mean baseline WBC approximately 6600 cells/microL) was observed due to a small increase in neutrophils. This observation was seen in most but not all studies. This change in laboratory parameters is not considered to be clinica lly releva nt.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal&nbsp;serum&nbsp;Vitamin&nbsp;B12 levels,&nbsp;without clinical&nbsp;manifestations,&nbsp;was&nbsp;observed in approximately 7%&nbsp;of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12 supplementation (see <strong>PRECAUTIONS</strong>, <em>Metformin </em><em>hydrochloride</em>).</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is very important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions online .</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi</u><u> </u><u>Arabia:</u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC</u><u> </u><u>States:</u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>During controlled clinical trials in healthy subjects, single dosesof up to 800 mg sitagliptin were genera <strong>l</strong>y well tolerated. Minimal increases in QTc, not considered to be clinically relevant, were observed in one study at a dose of 800 mg sitagliptin. There is no experience with doses above 800 mg in clinica l studies. In Phase I multiple-dose studies, there were no dose-rela ted clinica l adverse reactions observed with sitagliptin with doses of up to 600 mg per day for periods up to 10 days and 400 mg per day for periods of up to 28 days.</p><p>&nbsp;</p><p>In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinica l monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required.</p><p>&nbsp;</p><p>Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session. Prolonged hemodialysis may be considered if clinica lly appropriate. It is not known if sita gliptin is dia lyzable by peritoneal dia lysis.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see <strong>PRECAUTIONS</strong>, <em>Metformin hydrochloride</em>). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumula ted drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs, ATC code: A10BD07</p><p>Janumet XR combines two antihyperglycaemic medicinal products with complementary mechanisms</p><p>of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide cla ss.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Sitagliptin</u></p><p><em>Mechanism of action</em></p><p>Sitagliptin phosphate is a member of a class of oral anti-hyperglycemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors, which improve glycemic control in patients with type 2 diabetes by enhancing the levels of active incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increa se insulin synthesis and release from pancreatic beta cells by intra cellular signa ling pathways involving cyclic AMP. Treatment with GLP-1 or with DPP-4 inhibitors in animal models of type 2 diabetes has been demonstrated to improve beta cell responsiveness to glucose and stimulate insulin biosynthesis and release. With higher insulin levels, tissue glucose uptake is enhanced. In addition, GLP-1 lowers glucagon secretion from pancreatic alpha cells. Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels. The effects of GLP-1 a nd GIP are glucose-dependent such that when blood glucose concentrations are low, stimulation of insulin release and suppression of glucagon secretion by the incretin hormones GLP- 1 are not observed. For both GLP-1 and GIP, stimulation of insulin release is enhanced as glucose rises above normal concentrations. Further, GLP-1 and GIP does not impair the normal glucagon response to hypoglycemia. The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyzes the incretin hormones to produce inactive products. Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 a nd GIP. By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose- dependent manner. In patients with type 2 diabetes with hyperglycemia, these changes in insulin and glucagon levels lead to lower hemoglobin A1c (HbA1c) and lower fasting and postprandial glucose concentrations. The glucose-dependant mechanism of sita gliptin is distinct from the mechanism of sulfonylureas, which increases insulin secretion even when glucose levels are low and can lead to hypoglycemia in patients with type 2 diabetes and in normal subjects. Sita gliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.</p><p><em>.</em></p><p><u>Metformin hydrochloride</u></p><p><em>Mechanism of action</em></p><p><em>&nbsp;</em></p><p>Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetesor normal subjects (except in special circumstances, see <strong>PRECAUTIONS</strong>, <em>Metformin </em><em>hydrochloride</em>) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.</p><p>&nbsp;</p><p><em>Clinical Efficacy Clinical Studies</em></p><p>There were no clinical studies conducted with Janumet XR on efficacy and safety. Clinica l studies of the coadministration of sita gliptin and metformin without extended release demonstrated significant improvements in glycemic control in patients with type 2 diabetes. The bioequivalence between Janumet XR tablets a nd coadministered sita gliptin a nd extended-release metformin tablets was demonstrated for all tablet strengths.</p><p>In a comparative study, once daily administration of extended-release metformin had efficacy similar to the commonly prescribed twice daily administration of the metformin formulation without extended release in all measures of glycemic control.</p><p>&nbsp;</p><p>Sitagliptin and Metformin without extended release in Patients with Type 2 Diabetes</p><p><strong>&nbsp;</strong></p><p>A total of 1091 patients with type 2 diabetes and inadequate glycemic control on diet and exercise participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of therapy with the combination of sitagliptin and metformin.</p><p>&nbsp;</p><p>In patients with inadequate glycemic control on diet and exercise alone the combination of sitagliptin and metformin provided significant&nbsp;improvements&nbsp;in HbA1c,&nbsp;FPG,&nbsp;and 2-hour&nbsp;PPG&nbsp;compared to placebo,&nbsp;to metformin alone, and to sitagliptin alone (p&lt;0.001; Table 2, Figure 1). An improvement in FPG, with near maximal FPG reduction, was achieved by the 3-week time point (the first time point assessed after initiation of therapy) a nd sustained throughout the 24-week study. Mean reductions from baseline in HbA1c compared with placebo were generally greater for patients with higher baseline HbA1c values.</p><p>The improvement in HbA1c was generally consistent across subgroups defined by gender, age, race, or baseline BMI. Measures of beta cell function, HOMA-&beta; and the proinsulin to insulin ratio also showed greater improvement with the coadministration of sitagliptin and metformin compared with either monotherapy alone. Lipid effects were generally neutral. Mean reductions from baseline HbA1c for the sub-group of patients not on an antihyperglycemic agent at study entry were: sitagliptin 100 mg once daily (N=88), -1.06 %; metformin 500 mg bid (N=90), -1.09 %; metformin 1000 mg bid (N=87), -1.24 %; sitagliptin 50 mg bid with metformin 500 mg bid (N=100), -1.59 %; and sitagliptin 50 mg bid with metformin 1000mg bid (N=86), -1.94%; and for patients receiving pla cebo (N=83), -0.17 %.</p><p>&nbsp;</p><p>Figure 1: Mean Change from Baseline for HbA1c over 24 Weeks with Sitagliptin and Metformin, Alone and in Combination as Initial Therapy in Patients with Type 2 Diabetes&dagger;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:161.95pt;
 margin-top:-25.8pt;width:316.05pt;height:199.4pt;z-index:251642880;
 mso-position-horizontal-relative:page' coordorigin="3239,-516" coordsize="6321,3988"
 o:allowincell="f">
 <v:shape id="_x0000_s1027" style='position:absolute;left:3334;top:3374;
  width:6224;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6224,6" o:allowincell="f"
  path="m6223,hhl,,,5r6223,l6223,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1028" style='position:absolute;left:3333;top:3374;
  width:6224;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6224,6" o:allowincell="f"
  path="m,5hhl6223,5r,-5l,,,5xe" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:9555;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" style='position:absolute;left:3616;top:3378;
  width:1;height:95;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,95" o:allowincell="f"
  path="m,94hhl,e" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1031" style='position:absolute;left:3613;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:5031;top:3378;
  width:1;height:95;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,95" o:allowincell="f"
  path="m,94hhl,e" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1033" style='position:absolute;left:5029;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1034" style='position:absolute;left:6445;top:3378;
  width:1;height:95;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,95" o:allowincell="f"
  path="m,94hhl,e" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1035" style='position:absolute;left:6443;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1036" style='position:absolute;left:7860;top:3378;
  width:1;height:95;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,95" o:allowincell="f"
  path="m,94hhl,e" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1037" style='position:absolute;left:7857;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1038" style='position:absolute;left:9275;top:3378;
  width:1;height:95;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,95" o:allowincell="f"
  path="m,94hhl,e" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1039" style='position:absolute;left:9273;top:3375;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1040" style='position:absolute;left:3332;top:-514;
  width:4;height:3892;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,3892" o:allowincell="f"
  path="m3,hhl,,,3892r3,l3,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1041" style='position:absolute;left:3332;top:-514;
  width:4;height:3892;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,3892" o:allowincell="f"
  path="m,3892hhl3,3892,3,,,,,3892xe" filled="f" strokeweight=".09047mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1042" style='position:absolute;left:3331;top:-516;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1043" style='position:absolute;left:3239;top:3054;
  width:95;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="95,1" o:allowincell="f"
  path="m,hhl94,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1044" style='position:absolute;left:3331;top:3052;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1045" style='position:absolute;left:3239;top:2334;
  width:95;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="95,1" o:allowincell="f"
  path="m,hhl94,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1046" style='position:absolute;left:3331;top:2331;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1047" style='position:absolute;left:3239;top:1614;
  width:95;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="95,1" o:allowincell="f"
  path="m,hhl94,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1048" style='position:absolute;left:3331;top:1611;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1049" style='position:absolute;left:3239;top:893;
  width:95;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="95,1" o:allowincell="f"
  path="m,hhl94,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1050" style='position:absolute;left:3331;top:891;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1051" style='position:absolute;left:3239;top:173;
  width:95;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="95,1" o:allowincell="f"
  path="m,hhl94,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1052" style='position:absolute;left:3331;top:171;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1053" style='position:absolute;left:3272;top:2695;
  width:62;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="62,1" o:allowincell="f"
  path="m,hhl61,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1054" style='position:absolute;left:3331;top:2692;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1055" style='position:absolute;left:3272;top:1975;
  width:62;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="62,1" o:allowincell="f"
  path="m,hhl61,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1056" style='position:absolute;left:3331;top:1972;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1057" style='position:absolute;left:3272;top:1253;
  width:62;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="62,1" o:allowincell="f"
  path="m,hhl61,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1058" style='position:absolute;left:3331;top:1250;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1059" style='position:absolute;left:3272;top:532;
  width:62;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="62,1" o:allowincell="f"
  path="m,hhl61,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1060" style='position:absolute;left:3331;top:530;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1061" style='position:absolute;left:3272;top:-187;
  width:62;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="62,1" o:allowincell="f"
  path="m,hhl61,e" filled="f" strokeweight=".09053mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1062" style='position:absolute;left:3331;top:-189;
  width:6;height:6;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6,6" o:allowincell="f"
  path="m,2hhl,,2,,4,,5,2,4,4,2,5,,4,,2xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1063" style='position:absolute;left:3333;top:173;
  width:6190;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="6190,1" o:allowincell="f"
  path="m,hhl6189,e" filled="f" strokeweight=".18106mm">
  <v:stroke dashstyle="1 1"/>
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1064" style='position:absolute;left:3616;top:173;
  width:5830;height:2743;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5830,2743" o:allowincell="f"
  path="m,hhl1585,1642r1414,843l4414,2716r1415,26e" filled="f" strokeweight=".18103mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1065" style='position:absolute;left:5201;top:1739;
  width:1;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,154" o:allowincell="f"
  path="m,hhl,153e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1066" style='position:absolute;left:5196;top:1887;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1067" style='position:absolute;left:6615;top:2556;
  width:1;height:206;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,206" o:allowincell="f"
  path="m,hhl,205e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1068" style='position:absolute;left:6610;top:2757;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1069" style='position:absolute;left:8031;top:2777;
  width:1;height:226;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,226" o:allowincell="f"
  path="m,hhl,225e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1070" style='position:absolute;left:8025;top:2998;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1071" style='position:absolute;left:9445;top:2798;
  width:1;height:237;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,237" o:allowincell="f"
  path="m,hhl,236e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1072" style='position:absolute;left:9440;top:3029;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1073" style='position:absolute;left:3546;top:103;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1074" style='position:absolute;left:3546;top:103;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1075" style='position:absolute;left:5131;top:1745;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1076" style='position:absolute;left:5131;top:1745;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1077" style='position:absolute;left:6545;top:2589;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1078" style='position:absolute;left:6545;top:2589;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1079" style='position:absolute;left:7960;top:2820;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1080" style='position:absolute;left:7960;top:2820;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1081" style='position:absolute;left:9375;top:2846;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1082" style='position:absolute;left:9375;top:2846;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1083" style='position:absolute;left:3616;top:173;
  width:5761;height:1178;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5761,1178" o:allowincell="f"
  path="m,hhl1516,699r1416,324l4346,1156r1414,21e" filled="f" strokeweight=".18106mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1084" style='position:absolute;left:3610;top:168;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m10,5hhl8,1,5,,1,1,,5,1,8r4,2l8,8,10,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1085" style='position:absolute;left:5132;top:796;
  width:1;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,153" o:allowincell="f"
  path="m,hhl,152e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1086" style='position:absolute;left:5127;top:943;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1087" style='position:absolute;left:6548;top:1094;
  width:1;height:206;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,206" o:allowincell="f"
  path="m,hhl,205e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1088" style='position:absolute;left:6543;top:1294;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1089" style='position:absolute;left:7962;top:1217;
  width:1;height:226;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,226" o:allowincell="f"
  path="m,hhl,225e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1090" style='position:absolute;left:7957;top:1437;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1091" style='position:absolute;left:9376;top:1232;
  width:1;height:237;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,237" o:allowincell="f"
  path="m,hhl,236e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1092" style='position:absolute;left:9371;top:1463;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1093" style='position:absolute;left:3539;top:96;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1094" style='position:absolute;left:3539;top:96;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1095" style='position:absolute;left:5055;top:796;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1096" style='position:absolute;left:5055;top:796;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1097" style='position:absolute;left:6471;top:1119;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1098" style='position:absolute;left:6471;top:1119;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1099" style='position:absolute;left:7885;top:1253;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1100" style='position:absolute;left:7885;top:1253;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1101" style='position:absolute;left:9299;top:1273;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1102" style='position:absolute;left:9299;top:1273;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1103" style='position:absolute;left:3616;top:173;
  width:5693;height:2064;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5693,2064" o:allowincell="f"
  path="m,hhl1449,1272r1415,562l4278,2063r1414,-50e" filled="f" strokeweight=".18106mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1104" style='position:absolute;left:3610;top:168;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m10,5hhl8,1,5,,1,1,,5,1,8r4,2l8,8,10,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1105" style='position:absolute;left:5066;top:1371;
  width:1;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,153" o:allowincell="f"
  path="m,hhl,152e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1106" style='position:absolute;left:5060;top:1518;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1107" style='position:absolute;left:6480;top:1906;
  width:1;height:202;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,202" o:allowincell="f"
  path="m,hhl,201e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1108" style='position:absolute;left:6475;top:2103;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1109" style='position:absolute;left:7894;top:2125;
  width:1;height:223;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,223" o:allowincell="f"
  path="m,hhl,222e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1110" style='position:absolute;left:7889;top:2343;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1111" style='position:absolute;left:9308;top:2070;
  width:1;height:233;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,233" o:allowincell="f"
  path="m,hhl,232e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1112" style='position:absolute;left:9303;top:2298;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1113" style='position:absolute;left:3539;top:96;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1114" style='position:absolute;left:3539;top:96;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1115" style='position:absolute;left:4989;top:1369;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1116" style='position:absolute;left:4989;top:1369;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1117" style='position:absolute;left:6403;top:1930;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1118" style='position:absolute;left:6403;top:1930;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1119" style='position:absolute;left:7817;top:2159;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1120" style='position:absolute;left:7817;top:2159;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1121" style='position:absolute;left:9231;top:2110;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl,76r76,77l153,76,76,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1122" style='position:absolute;left:9231;top:2110;
  width:154;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="154,154" o:allowincell="f"
  path="m76,hhl153,76,76,153,,76,76,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1123" style='position:absolute;left:3616;top:173;
  width:5626;height:957;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5626,957" o:allowincell="f"
  path="m,hhl1381,627,2795,863r1414,76l5625,956e" filled="f" strokeweight=".18106mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1124" style='position:absolute;left:3610;top:168;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m10,5hhl8,1,5,,1,1,,5,1,8r4,2l8,8,10,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1125" style='position:absolute;left:4997;top:724;
  width:1;height:154;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,154" o:allowincell="f"
  path="m,hhl,153e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1126" style='position:absolute;left:4992;top:873;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1127" style='position:absolute;left:6411;top:933;
  width:1;height:209;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,209" o:allowincell="f"
  path="m,hhl,208e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1128" style='position:absolute;left:6406;top:1136;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1129" style='position:absolute;left:7825;top:999;
  width:1;height:228;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,228" o:allowincell="f"
  path="m,hhl,227e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1130" style='position:absolute;left:7820;top:1222;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1131" style='position:absolute;left:9241;top:1010;
  width:1;height:238;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,238" o:allowincell="f"
  path="m,hhl,237e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1132" style='position:absolute;left:9236;top:1242;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1133" style='position:absolute;left:3539;top:96;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1134" style='position:absolute;left:3539;top:96;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1135" style='position:absolute;left:4920;top:724;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1136" style='position:absolute;left:4920;top:724;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1137" style='position:absolute;left:6334;top:960;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1138" style='position:absolute;left:6334;top:960;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1139" style='position:absolute;left:7748;top:1035;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1140" style='position:absolute;left:7748;top:1035;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1141" style='position:absolute;left:9164;top:1052;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1142" style='position:absolute;left:9164;top:1052;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1143" style='position:absolute;left:3616;top:173;
  width:5558;height:1626;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5558,1626" o:allowincell="f"
  path="m,hhl1313,898r1414,474l4143,1582r1414,43e" filled="f" strokeweight=".18106mm">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1144" style='position:absolute;left:4924;top:998;
  width:11;height:147' coordorigin="4924,998" coordsize="11,147" o:allowincell="f">
  <v:shape id="_x0000_s1145" style='position:absolute;left:4924;top:998;
   width:11;height:147;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="11,147" o:allowincell="f"
   path="m,146hhl10,146e" filled="f" strokeweight=".15089mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1146" style='position:absolute;left:4924;
   top:998;width:11;height:147;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="11,147" o:allowincell="f"
   path="m,hhl10,e" filled="f" strokeweight=".15089mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1147" style='position:absolute;
  left:4924;top:1143;width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1148" style='position:absolute;left:6343;top:1441;
  width:1;height:208' coordorigin="6343,1441" coordsize="1,208" o:allowincell="f">
  <v:shape id="_x0000_s1149" style='position:absolute;left:6343;top:1441;
   width:1;height:208;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,208" o:allowincell="f"
   path="m,172hhl,207e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1150" style='position:absolute;left:6343;
   top:1441;width:1;height:208;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,208" o:allowincell="f"
   path="m,hhl,34e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1151" style='position:absolute;
  left:6338;top:1643;width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1152" style='position:absolute;left:7759;top:1643;
  width:1;height:226' coordorigin="7759,1643" coordsize="1,226" o:allowincell="f">
  <v:shape id="_x0000_s1153" style='position:absolute;left:7759;top:1643;
   width:1;height:226;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,226" o:allowincell="f"
   path="m,181hhl,225e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1154" style='position:absolute;left:7759;
   top:1643;width:1;height:226;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,226" o:allowincell="f"
   path="m,hhl,42e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1155" style='position:absolute;
  left:7754;top:1863;width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1156" style='position:absolute;left:9173;top:1680;
  width:1;height:237' coordorigin="9173,1680" coordsize="1,237" o:allowincell="f">
  <v:shape id="_x0000_s1157" style='position:absolute;left:9173;top:1680;
   width:1;height:237;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,237" o:allowincell="f"
   path="m,186hhl,236e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1158" style='position:absolute;left:9173;
   top:1680;width:1;height:237;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="1,237" o:allowincell="f"
   path="m,hhl,47e" filled="f" strokeweight=".18094mm">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1159" style='position:absolute;
  left:9168;top:1911;width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1160" style='position:absolute;left:3546;top:103;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1161" style='position:absolute;left:3546;top:103;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1162" style='position:absolute;left:4859;top:1001;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1163" style='position:absolute;left:4859;top:1001;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1164" style='position:absolute;left:6273;top:1475;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1165" style='position:absolute;left:6273;top:1475;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1166" style='position:absolute;left:7689;top:1686;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1167" style='position:absolute;left:7689;top:1686;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1168" style='position:absolute;left:9103;top:1728;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m138,hhl,,,138r138,l138,xe" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1169" style='position:absolute;left:9103;top:1728;
  width:139;height:139;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="139,139" o:allowincell="f"
  path="m,hhl138,r,138l,138,,xe" filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1170" style='position:absolute;left:3616;top:-69;
  width:5489;height:242;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="5489,242" o:allowincell="f"
  path="m,242hhl1244,102,2660,99,4074,30,5488,e" filled="f" strokeweight=".18106mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1171" style='position:absolute;left:3610;top:168;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m10,5hhl8,1,5,,1,1,,5,1,8r4,2l8,8,10,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1172" style='position:absolute;left:4860;top:-45;
  width:1;height:159;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,159" o:allowincell="f"
  path="m,hhl,159e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1173" style='position:absolute;left:4855;top:108;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1174" style='position:absolute;left:6276;top:-77;
  width:1;height:213;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,213" o:allowincell="f"
  path="m,hhl,213e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1175" style='position:absolute;left:6271;top:130;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1176" style='position:absolute;left:7690;top:-156;
  width:1;height:234;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,234" o:allowincell="f"
  path="m,hhl,234e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1177" style='position:absolute;left:7685;top:72;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1178" style='position:absolute;left:9104;top:-190;
  width:1;height:244;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,244" o:allowincell="f"
  path="m,hhl,244e" filled="f" strokeweight=".18094mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1179" style='position:absolute;left:9099;top:48;
  width:11;height:11;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="11,11" o:allowincell="f"
  path="m,5hhl1,1,5,,8,1r2,4l8,8,5,10,1,8,,5xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1180" style='position:absolute;left:3539;top:96;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1181" style='position:absolute;left:3539;top:96;
  width:153;height:153;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,153" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1182" style='position:absolute;left:4783;top:-43;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1183" style='position:absolute;left:4783;top:-43;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1184" style='position:absolute;left:6199;top:-47;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1185" style='position:absolute;left:6199;top:-47;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1186" style='position:absolute;left:7613;top:-115;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1187" style='position:absolute;left:7613;top:-115;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1188" style='position:absolute;left:9027;top:-146;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m76,hhl46,5,22,22,5,46,,76r5,29l22,130r24,16l76,152r29,-6l129,130r17,-25l152,76,146,46,129,22,105,5,76,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1189" style='position:absolute;left:9027;top:-146;
  width:153;height:152;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="153,152" o:allowincell="f"
  path="m,76hhl5,46,22,22,46,5,76,r29,5l129,22r17,24l152,76r-6,29l129,130r-24,16l76,152,46,146,22,130,5,105,,76xe"
  filled="f" strokeweight=".39219mm">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="423" height="268" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1195" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:118.4pt;margin-top:1.65pt;width:12.9pt;
 height:139.85pt;z-index:251646976;mso-position-horizontal-relative:page'
 o:allowincell="f" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.9pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><span style='font-size:9.5pt;
    font-family:"Arial",sans-serif'>LS<span style='letter-spacing:.35pt'> </span>Mean<span
    style='letter-spacing:.35pt'> </span>Change<span style='letter-spacing:
    .4pt'> </span>from<span style='letter-spacing:.45pt'> </span><span
    style='letter-spacing:-.1pt'>Baseline<o:p></o:p></span></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="21" height="190" alt="Text Box: LS Mean Change from Baseline" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" />0.0</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.5</p><p>&nbsp;</p><p>&nbsp;</p><p>-1.0</p><p>&nbsp;</p><p>&nbsp;</p><p>-1.5</p><p>&nbsp;</p><p>&nbsp;</p><p>-2.0</p><p>&nbsp;</p><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24</p><p>&nbsp;</p><p>Week</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:9pt;
 height:9pt'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="12" height="12" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" />&nbsp;Placebo</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1191" style='position:absolute;left:0;text-align:left;
 margin-left:151.2pt;margin-top:26.15pt;width:7.7pt;height:7.7pt;z-index:-251671552;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="154,154" o:allowincell="f" path="m76,hhl153,76,76,153,,76,76,e"
 filled="f" strokeweight=".39219mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="15" height="14" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png" /><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:6.75pt;height:6.75pt'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="9" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png" />&nbsp;Sitagliptin 100 mg q.d. Metformin 500 mg b.i.d.</p><p>&nbsp;</p><p>Metformin 1000 mg b.i.d.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1190" style='position:absolute;left:0;text-align:left;
 margin-left:291.35pt;margin-top:-8.75pt;width:7.45pt;height:7.45pt;z-index:251643904;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="149,149" o:allowincell="f" path="m,hhl148,r,148l,148,,xe" filled="f"
 strokeweight=".39219mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="13" height="13" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png" /><!--[if gte vml 1]><v:group
 id="_x0000_s1192" style='position:absolute;left:0;text-align:left;
 margin-left:291.85pt;margin-top:26.7pt;width:6.45pt;height:6.45pt;z-index:-251670528;
 mso-position-horizontal-relative:page' coordorigin="5837,534" coordsize="129,129"
 o:allowincell="f">
 <v:shape id="_x0000_s1193" style='position:absolute;left:5837;top:534;width:129;
  height:129;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="129,129" o:allowincell="f"
  path="m128,hhl,,,128r128,l128,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1194" style='position:absolute;left:5837;top:534;
  width:129;height:129;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="129,129" o:allowincell="f"
  path="m,hhl128,r,128l,128,,xe" filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="11" height="11" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png" /><!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75"
 style='width:7.5pt;height:7.5pt'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image010.png"
  o:title=""/>
</v:shape><![endif]--><img width="10" height="10" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image011.png" />&nbsp;Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. Sitagliptin 50 mg b.i.d. + Metformin 1000 mg b.i.d.</p><p>&nbsp;</p><p><sup>&dagger;</sup>All Patients Trea ted Population Least squares means adjusted for prior antihyperglycemic therapy and baseline value.</p><p>&nbsp;</p><p>Table 2</p><p><strong>Glycemic Parameters and Body Weight at Final Visit after 24-Weeks</strong><sup>&dagger;</sup></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Sitagliptin </strong><strong>100 mg q.d.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Metformi </strong><strong>n</strong></p><p><strong>500</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; mg b.i.d.</strong></p></td><td style="vertical-align:top"><p><strong>Sitaglipti</strong></p><p><strong>n</strong></p><p><strong>50</strong><strong> </strong><strong>mg</strong></p><p><strong>b.i.d. + Metform in</strong></p><p><strong>500 mg b.i.d.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Metform </strong><strong>in</strong></p><p><strong>1000 mg b.i.d.</strong></p></td><td style="vertical-align:top"><p><strong>Sitaglipti</strong></p><p><strong>n</strong></p><p><strong>50</strong><strong> </strong><strong>mg</strong></p><p><strong>b.i.d + Metformi n</strong></p><p><strong>1000 mg b.i.d.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 165</strong></p></td><td style="vertical-align:top"><p><strong>N = 175</strong></p></td><td style="vertical-align:top"><p><strong>N = 178</strong></p></td><td style="vertical-align:top"><p><strong>N = 183</strong></p></td><td style="vertical-align:top"><p><strong>N = 177</strong></p></td><td style="vertical-align:top"><p><strong>N = 178</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.68</p></td><td style="vertical-align:top"><p>8.87</p></td><td style="vertical-align:top"><p>8.90</p></td><td style="vertical-align:top"><p>8.79</p></td><td style="vertical-align:top"><p>8.68</p></td><td style="vertical-align:top"><p>8.76</p></td></tr><tr><td style="vertical-align:top"><p>Cha nge from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>0.17</p></td><td style="vertical-align:top"><p>-0.66</p></td><td style="vertical-align:top"><p>-0.82</p></td><td style="vertical-align:top"><p>-1.40</p></td><td style="vertical-align:top"><p>-1.13</p></td><td style="vertical-align:top"><p>-1.90</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-0.83<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-0.99<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-1.57<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-1.30<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-2.07<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Patients (%) achieving HbA1c &lt;7%</p></td><td style="vertical-align:top"><p>15 (9.1)</p></td><td style="vertical-align:top"><p>35 (20.0)</p></td><td style="vertical-align:top"><p>41 (23.0)</p></td><td style="vertical-align:top"><p>79 (43.2)</p></td><td style="vertical-align:top"><p>68 (38.4)</p></td><td style="vertical-align:top"><p>118 (66.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>FPG </strong><strong>(mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 169</strong></p></td><td style="vertical-align:top"><p><strong>N = 178</strong></p></td><td style="vertical-align:top"><p><strong>N = 179</strong></p></td><td style="vertical-align:top"><p><strong>N = 183</strong></p></td><td style="vertical-align:top"><p><strong>N = 179</strong></p></td><td style="vertical-align:top"><p><strong>N = 180</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>10.91</p></td><td style="vertical-align:top"><p>11.19</p></td><td style="vertical-align:top"><p>11.40</p></td><td style="vertical-align:top"><p>11.33</p></td><td style="vertical-align:top"><p>10.94</p></td><td style="vertical-align:top"><p>10.93</p></td></tr><tr><td style="vertical-align:top"><p>Cha nge from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>0.32</p></td><td style="vertical-align:top"><p>-0.97</p></td><td style="vertical-align:top"><p>-1.52</p></td><td style="vertical-align:top"><p>-2.62</p></td><td style="vertical-align:top"><p>-1.63</p></td><td style="vertical-align:top"><p>-3.55</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-1.29<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-1.84<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-2.94<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-1.95<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-3.87<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour</strong><strong> </strong><strong>PPG (mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 129</strong></p></td><td style="vertical-align:top"><p><strong>N = 136</strong></p></td><td style="vertical-align:top"><p><strong>N = 141</strong></p></td><td style="vertical-align:top"><p><strong>N = 147</strong></p></td><td style="vertical-align:top"><p><strong>N = 138</strong></p></td><td style="vertical-align:top"><p><strong>N = 152</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>15.38</p></td><td style="vertical-align:top"><p>15.86</p></td><td style="vertical-align:top"><p>16.26</p></td><td style="vertical-align:top"><p>16.21</p></td><td style="vertical-align:top"><p>15.74</p></td><td style="vertical-align:top"><p>15.94</p></td></tr><tr><td style="vertical-align:top"><p>Cha nge from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>0.02</p></td><td style="vertical-align:top"><p>-2.88</p></td><td style="vertical-align:top"><p>-2.97</p></td><td style="vertical-align:top"><p>-5.14</p></td><td style="vertical-align:top"><p>-4.33</p></td><td style="vertical-align:top"><p>-6.48</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>-2.9<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-2.98<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-5.16<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-4.35<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>-6.49<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body</strong><strong> </strong><strong>Weight</strong><strong> </strong><strong>(kg)</strong><sup>%</sup></p></td><td style="vertical-align:top"><p><strong>N = 167</strong></p></td><td style="vertical-align:top"><p><strong>N = 175</strong></p></td><td style="vertical-align:top"><p><strong>N = 179</strong></p></td><td style="vertical-align:top"><p><strong>N = 184</strong></p></td><td style="vertical-align:top"><p><strong>N = 175</strong></p></td><td style="vertical-align:top"><p><strong>N = 178</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>90.1</p></td><td style="vertical-align:top"><p>85.9</p></td><td style="vertical-align:top"><p>88.1</p></td><td style="vertical-align:top"><p>90.0</p></td><td style="vertical-align:top"><p>89.4</p></td><td style="vertical-align:top"><p>88.2</p></td></tr><tr><td style="vertical-align:top"><p>Cha nge from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.9</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>-0.9</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-1.1</p></td><td style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.9<sup>&para;</sup></p></td><td style="vertical-align:top"><p>0.1<sup>#</sup></p></td><td style="vertical-align:top"><p>0.4<sup>#</sup></p></td><td style="vertical-align:top"><p>-0.1<sup>#</sup></p></td><td style="vertical-align:top"><p>-0.3<sup>#</sup></p></td></tr></tbody></table><p><!--[if gte vml 1]><v:group
 id="_x0000_s1196" style='position:absolute;left:0;text-align:left;
 margin-left:338.4pt;margin-top:-6.15pt;width:3.2pt;height:1.6pt;z-index:-251668480;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordorigin="6768,-123" coordsize="64,32" o:allowincell="f">
 <v:shape id="_x0000_s1197" style='position:absolute;left:6768;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m63,16hhl,16,,32r63,l63,16xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1198" style='position:absolute;left:6768;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m63,hhl,,,16r63,l63,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="2" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png" /><!--[if gte vml 1]><v:group
 id="_x0000_s1199" style='position:absolute;left:0;text-align:left;
 margin-left:392.8pt;margin-top:-6.15pt;width:3.2pt;height:1.6pt;z-index:-251667456;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordorigin="7856,-123" coordsize="64,32" o:allowincell="f">
 <v:shape id="_x0000_s1200" style='position:absolute;left:7856;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,16hhl,16,,32r64,l64,16xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1201" style='position:absolute;left:7856;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,hhl,,,16r64,l64,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="2" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png" /><!--[if gte vml 1]><v:group
 id="_x0000_s1202" style='position:absolute;left:0;text-align:left;
 margin-left:445.6pt;margin-top:-6.15pt;width:3.2pt;height:1.6pt;z-index:-251666432;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordorigin="8912,-123" coordsize="64,32" o:allowincell="f">
 <v:shape id="_x0000_s1203" style='position:absolute;left:8912;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,16hhl,16,,32r64,l64,16xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1204" style='position:absolute;left:8912;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,hhl,,,16r64,l64,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="2" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png" /><!--[if gte vml 1]><v:group
 id="_x0000_s1205" style='position:absolute;left:0;text-align:left;
 margin-left:496pt;margin-top:-6.15pt;width:3.2pt;height:1.6pt;z-index:-251665408;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordorigin="9920,-123" coordsize="64,32" o:allowincell="f">
 <v:shape id="_x0000_s1206" style='position:absolute;left:9920;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,16hhl,16,,32r64,l64,16xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1207" style='position:absolute;left:9920;top:-123;
  width:64;height:32;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,32" o:allowincell="f"
  path="m64,hhl,,,16r64,l64,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="2" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image013.png" /><sup>&dagger;</sup> All Patients Treated Population (an intention-to-treat analysis).</p><p><sup>&Dagger;</sup> Least squares means adjusted for prior antihyperglycemic therapy status and baseline value.</p><p><sup>&sect;</sup> p&lt;0.001 compared to placebo.</p><p><sup>%</sup> All Patients as Treated (APa T) population, excluding data following glycemic rescue therapy.</p><p><sup>&para;</sup> p=0.005 compared to placebo.</p><p><u><sup>#</sup> </u>Not statistically significant (p&sup3;0.05) compared to placebo.</p><p>&nbsp;</p><p>In addition, this study included patients (N=117) with more severe hyperglycemia (HbA1c &gt;11% or blood glucose &gt;15.56 mmol/L) who were treated with sitagliptin at 50 mg and metformin at 1000 mg twice daily. There was no placebo control for these patients. In this group of patients, the baseline HbA1c value was on average 11.15%, FPG wa s 17.4 mmol/L, and 2-hour PPG was 24.5 mmol/L. At 24 weeks, decreases from baseline of&nbsp;-2.94&nbsp;% for HbA1c, -7.04 mmol/L for FPG, and&nbsp;-11.55 mmol/L for 2-hour PPG were observed. In this cohort, an increase in body weight of 1.3 kg was observed at 24 weeks.</p><p>&nbsp;</p><p>Sitagliptin Add-on Therapy in Patients Inadequately Controlled on Metformin Alone:</p><p><strong>&nbsp;</strong></p><p>The combination of sitagliptin and metformin without extended release has been evaluated for safety and efficacy in two double-blind, placebo-controlled clinical studies in patients with type 2 diabetes mellitus. In both studies, patients with inadequate glycemic control on stable doses of metformin &ge;1500 mg were randomized to receive either sitagliptin 100 mg per day or placebo in a ddition to ongoing treatment with metformin.</p><p>&nbsp;</p><p>In one study, 701 patients received 100 mg of sitagliptin or placebo once daily for 24 weeks. The addition of sitagliptin to ongoing metformin treatmentwithout extended release provided significant improvements compared with the addition of placebo to ongoing metformin treatment in HbA1c (-0.65%), FPG (-1.41 mmol/L), and 2-hour PPG (-2.81 mmol/L) (see Figure 2 and Table 3). This improvement in HbA1c compared&nbsp;to&nbsp;placebo&nbsp;was&nbsp;not&nbsp;affected&nbsp;by&nbsp;baseline&nbsp;HbA1c value,&nbsp;prior&nbsp;antihyperglycemic&nbsp;therapy,&nbsp;gender,</p><p>&nbsp;</p><p>age, baseline BMI, length of time since diagnosis of diabetes, presence of metabolic syndrome, or standard indices of insulin resista nce (HOMA-IR) or insulin secretion (HOMA-&beta;).</p><p>&nbsp;</p><p>Figure 2: Mean Change from Baseline for HbA1c over 24 Weeks with Sitagliptin 100-mg Total Daily Dose and Metformin or Placebo and Metformin in Patients with Type 2 Diabetes&dagger; &Dagger;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1208"
 style='position:absolute;left:0;text-align:left;margin-left:123pt;
 margin-top:-14.75pt;width:203.7pt;height:153.65pt;z-index:251652096;
 mso-position-horizontal-relative:page' coordorigin="2460,-295" coordsize="4074,3073"
 o:allowincell="f">
 <v:shape id="_x0000_s1209" style='position:absolute;left:2520;top:2715;
  width:4011;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4011,4" o:allowincell="f"
  path="m4010,hhl,,,3r4010,l4010,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1210" style='position:absolute;left:2520;top:2715;
  width:4011;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4011,4" o:allowincell="f"
  path="m,3hhl4010,3r,-3l,,,3xe" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1211" style='position:absolute;left:6530;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1212" style='position:absolute;left:2702;top:2717;
  width:1;height:61;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,61" o:allowincell="f"
  path="m,60hhl,e" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1213" style='position:absolute;left:2701;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1214" style='position:absolute;left:3615;top:2717;
  width:1;height:61;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,61" o:allowincell="f"
  path="m,60hhl,e" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1215" style='position:absolute;left:3613;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1216" style='position:absolute;left:4526;top:2717;
  width:1;height:61;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,61" o:allowincell="f"
  path="m,60hhl,e" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1217" style='position:absolute;left:4524;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1218" style='position:absolute;left:5437;top:2717;
  width:1;height:61;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,61" o:allowincell="f"
  path="m,60hhl,e" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1219" style='position:absolute;left:5436;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1220" style='position:absolute;left:6350;top:2717;
  width:1;height:61;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,61" o:allowincell="f"
  path="m,60hhl,e" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1221" style='position:absolute;left:6348;top:2715;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1222" style='position:absolute;left:2519;top:-294;
  width:3;height:3011;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="3,3011" o:allowincell="f"
  path="m2,hhl,,,3011r2,l2,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1223" style='position:absolute;left:2519;top:-294;
  width:3;height:3011;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="3,3011" o:allowincell="f"
  path="m,3011hhl2,3011,2,,,,,3011xe" filled="f" strokeweight=".05831mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1224" style='position:absolute;left:2519;top:-295;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1225" style='position:absolute;left:2460;top:2484;
  width:61;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="61,1" o:allowincell="f"
  path="m,hhl60,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1226" style='position:absolute;left:2519;top:2483;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1227" style='position:absolute;left:2460;top:1904;
  width:61;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="61,1" o:allowincell="f"
  path="m,hhl60,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1228" style='position:absolute;left:2519;top:1902;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1229" style='position:absolute;left:2460;top:1323;
  width:61;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="61,1" o:allowincell="f"
  path="m,hhl60,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1230" style='position:absolute;left:2519;top:1321;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1231" style='position:absolute;left:2460;top:742;
  width:61;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="61,1" o:allowincell="f"
  path="m,hhl60,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1232" style='position:absolute;left:2519;top:741;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1233" style='position:absolute;left:2460;top:162;
  width:61;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="61,1" o:allowincell="f"
  path="m,hhl60,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1234" style='position:absolute;left:2519;top:160;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1235" style='position:absolute;left:2481;top:2194;
  width:40;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="40,1" o:allowincell="f"
  path="m,hhl39,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1236" style='position:absolute;left:2519;top:2192;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1237" style='position:absolute;left:2481;top:1614;
  width:40;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="40,1" o:allowincell="f"
  path="m,hhl39,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1238" style='position:absolute;left:2519;top:1612;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1239" style='position:absolute;left:2481;top:1032;
  width:40;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="40,1" o:allowincell="f"
  path="m,hhl39,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1240" style='position:absolute;left:2519;top:1031;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1241" style='position:absolute;left:2481;top:452;
  width:40;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="40,1" o:allowincell="f"
  path="m,hhl39,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1242" style='position:absolute;left:2519;top:451;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1243" style='position:absolute;left:2481;top:-127;
  width:40;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="40,1" o:allowincell="f"
  path="m,hhl39,e" filled="f" strokeweight=".05836mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1244" style='position:absolute;left:2519;top:-129;
  width:4;height:4;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="4,4" o:allowincell="f"
  path="m,1hhl,,1,,2,,3,1,2,2,1,3,,2,,1xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1245" style='position:absolute;left:2521;top:162;
  width:3989;height:1;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="3989,1" o:allowincell="f"
  path="m,hhl3988,e" filled="f" strokeweight=".11675mm">
  <v:stroke dashstyle="1 1"/>
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1246" style='position:absolute;left:2702;top:114;
  width:3713;height:313;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="3713,313" o:allowincell="f"
  path="m,48hhl977,312,1889,139,2801,r911,118e" filled="f" strokeweight=".11675mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1247" style='position:absolute;left:2699;top:159;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m6,3hhl5,,3,,,,,3,,5,3,6,5,5,6,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1248" style='position:absolute;left:3680;top:313;
  width:1;height:227;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,227" o:allowincell="f"
  path="m,hhl,226e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1249" style='position:absolute;left:3676;top:536;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1250" style='position:absolute;left:4592;top:94;
  width:1;height:318;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,318" o:allowincell="f"
  path="m,hhl,317e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1251" style='position:absolute;left:4589;top:408;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1252" style='position:absolute;left:5503;top:-61;
  width:1;height:350;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,350" o:allowincell="f"
  path="m,hhl,350e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1253" style='position:absolute;left:5500;top:286;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1254" style='position:absolute;left:6415;top:51;
  width:1;height:362;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,362" o:allowincell="f"
  path="m,hhl,361e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1255" style='position:absolute;left:2699;top:110;
  width:3719;height:319' coordorigin="2699,110" coordsize="3719,319"
  o:allowincell="f">
  <v:shape id="_x0000_s1256" style='position:absolute;left:2699;top:110;
   width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m6,51hhl5,49,3,48,,49r,2l,54r3,1l5,54,6,51xe" fillcolor="black"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1257" style='position:absolute;left:2699;
   top:110;width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m984,315hhl983,313r-3,-1l978,313r-1,2l978,317r2,1l983,317r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1258" style='position:absolute;left:2699;
   top:110;width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m1896,142hhl1895,139r-2,l1890,139r-1,3l1890,144r3,1l1895,144r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1259" style='position:absolute;left:2699;
   top:110;width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m2807,3hhl2806,r-2,l2802,r-1,3l2802,5r2,1l2806,5r1,-2xe" fillcolor="black"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1260" style='position:absolute;left:2699;
   top:110;width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m3718,302hhl3717,299r-2,-1l3713,299r-1,3l3713,304r2,1l3717,304r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1261" style='position:absolute;left:2699;
   top:110;width:3719;height:319;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3719,319" o:allowincell="f"
   path="m3718,121hhl3717,119r-2,-1l3713,119r-1,2l3713,123r2,1l3717,123r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1262" style='position:absolute;
  left:2640;top:99;width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1263" style='position:absolute;left:2640;top:99;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight=".25281mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1264" style='position:absolute;left:3617;top:363;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1265" style='position:absolute;left:3617;top:363;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight=".25281mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1266" style='position:absolute;left:4529;top:190;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1267" style='position:absolute;left:4529;top:190;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight=".25281mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1268" style='position:absolute;left:5441;top:51;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1269" style='position:absolute;left:5441;top:51;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight=".25281mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1270" style='position:absolute;left:6352;top:169;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1271" style='position:absolute;left:6352;top:169;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight=".25281mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1272" style='position:absolute;left:2702;top:162;
  width:3626;height:1959;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="3626,1959" o:allowincell="f"
  path="m,hhl890,1451r911,372l2712,1848r913,110e" filled="f" strokeweight=".1167mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1273" style='position:absolute;left:2699;top:159;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m6,3hhl5,,3,,,,,3,,5,3,6,5,5,6,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1274" style='position:absolute;left:3593;top:1522;
  width:1;height:184;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,184" o:allowincell="f"
  path="m,hhl,183e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1275" style='position:absolute;left:3589;top:1702;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1276" style='position:absolute;left:4504;top:1855;
  width:1;height:260;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,260" o:allowincell="f"
  path="m,hhl,259e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1277" style='position:absolute;left:4501;top:2111;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1278" style='position:absolute;left:5415;top:1869;
  width:1;height:286;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,286" o:allowincell="f"
  path="m,hhl,285e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1279" style='position:absolute;left:5412;top:2151;
  width:7;height:7;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="7,7" o:allowincell="f"
  path="m,3hhl,,3,,5,,6,3,5,5,3,6,,5,,3xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1280" style='position:absolute;left:6328;top:1972;
  width:1;height:296;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="1,296" o:allowincell="f"
  path="m,hhl,295e" filled="f" strokeweight=".1166mm">
  <v:path arrowok="t"/>
 </v:shape><v:group id="_x0000_s1281" style='position:absolute;left:2699;top:159;
  width:3632;height:2113' coordorigin="2699,159" coordsize="3632,2113"
  o:allowincell="f">
  <v:shape id="_x0000_s1282" style='position:absolute;left:2699;top:159;
   width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m6,3hhl5,,3,,,,,3,,5,3,6,5,5,6,3xe" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1283" style='position:absolute;left:2699;
   top:159;width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m896,1455hhl895,1452r-2,-1l891,1452r-1,3l891,1457r2,1l895,1457r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1284" style='position:absolute;left:2699;
   top:159;width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m1808,1826hhl1807,1824r-3,-1l1802,1824r-1,2l1802,1829r2,1l1807,1829r1,-3xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1285" style='position:absolute;left:2699;
   top:159;width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m2719,1852hhl2718,1849r-2,-1l2713,1849r-1,3l2713,1854r3,1l2718,1854r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1286" style='position:absolute;left:2699;
   top:159;width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m3631,2109hhl3630,2106r-2,-1l3626,2106r-1,3l3626,2111r2,1l3630,2111r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1287" style='position:absolute;left:2699;
   top:159;width:3632;height:2113;mso-position-horizontal-relative:page;
   mso-position-vertical-relative:text' coordsize="3632,2113" o:allowincell="f"
   path="m3631,1961hhl3630,1959r-2,-1l3626,1959r-1,2l3626,1963r2,1l3630,1963r1,-2xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:shape id="_x0000_s1288" style='position:absolute;
  left:2640;top:99;width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1289" style='position:absolute;left:2640;top:99;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1290" style='position:absolute;left:3530;top:1551;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1291" style='position:absolute;left:3530;top:1551;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1292" style='position:absolute;left:4441;top:1923;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1293" style='position:absolute;left:4441;top:1923;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1294" style='position:absolute;left:5352;top:1948;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1295" style='position:absolute;left:5352;top:1948;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1296" style='position:absolute;left:6265;top:2057;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m62,hhl37,4,18,18,4,37,,62,4,86r14,20l37,119r25,5l86,119r20,-13l119,86r5,-24l119,37,106,18,86,4,62,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1297" style='position:absolute;left:6265;top:2057;
  width:125;height:125;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="125,125" o:allowincell="f"
  path="m,62hhl4,37,18,18,37,4,62,,86,4r20,14l119,37r5,25l119,86r-13,20l86,119r-24,5l37,119,18,106,4,86,,62xe"
  filled="f" strokeweight="0">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="273" height="207" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image014.png" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1299" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:89.5pt;margin-top:12.1pt;width:10.6pt;height:99.1pt;
 z-index:251654144;mso-position-horizontal-relative:page' o:allowincell="f"
 filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.9pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><span style='font-size:7.5pt;
    font-family:"Arial",sans-serif'>Mean<span style='letter-spacing:.3pt'> </span>Change<span
    style='letter-spacing:.2pt'> </span>from<span style='letter-spacing:.35pt'>
    </span><span style='letter-spacing:-.1pt'>Baseline<o:p></o:p></span></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="18" height="136" alt="Text Box: Mean Change from Baseline" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image015.png" />0.0</p><p>&nbsp;</p><p>-0.2</p><p>&nbsp;</p><p>-0.4</p><p>&nbsp;</p><p>-0.6</p><p>&nbsp;</p><p>-0.8</p><p>&nbsp;</p><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24</p><p>Week</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1298"
 style='position:absolute;left:0;text-align:left;margin-left:125.7pt;
 margin-top:6.45pt;width:6pt;height:6pt;z-index:251653120;
 mso-position-horizontal-relative:page' o:allowincell="f" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><!--[if gte vml 1]><v:shape id="_x0000_i1029"
     type="#_x0000_t75" style='width:6pt;height:6pt'>
     <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image016.png"
      o:title=""/>
    </v:shape><![endif]--><img width="8" height="8" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image017.png" /></p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>Sitagliptin and Metformin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:6.75pt;height:7.5pt'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image018.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="10" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image019.png" />&nbsp;Placebo and Metformin</p><p>&nbsp;</p><p>&nbsp;</p><p><sup>&dagger;</sup> Patients with inadequate glycemic control on metformin monotherapy.</p><p><sup>&Dagger;</sup> All Patients Treated Population Least squares means a djusted for prior antihyperglycemic therapy and baseline value.</p><p>&nbsp;</p><p>Table 3: Glycemic Parameters and Body Weight at Final Visit (24-Week Study)</p><p><strong>Sitagliptin as Add-on Therapy in Patients with Inadequate Glycemic Control on Metformin </strong><strong>&dagger;</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sitagliptin 100 mg q.d. + Metformin</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + Metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 453</strong></p></td><td style="vertical-align:top"><p><strong>N = 224</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>7.96</p></td><td style="vertical-align:top"><p>8.03</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.67</p></td><td style="vertical-align:top"><p>-0.02</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted</p></td><td style="vertical-align:top"><p>-0.65<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients&nbsp;(%)&nbsp;achieving&nbsp;HbA1c &lt;7%</p></td><td style="vertical-align:top"><p>213 (47.0)</p></td><td style="vertical-align:top"><p>41 (18.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>FPG </strong><strong>(mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 454</strong></p></td><td style="vertical-align:top"><p><strong>N = 226</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>9.44</p></td><td style="vertical-align:top"><p>9.64</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.94</p></td><td style="vertical-align:top"><p>0.47</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted</p></td><td style="vertical-align:top"><p>-1.41<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour</strong><strong> </strong><strong>PPG (mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 387</strong></p></td><td style="vertical-align:top"><p><strong>N = 182</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>15.25</p></td><td style="vertical-align:top"><p>15.13</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-3.44</p></td><td style="vertical-align:top"><p>-0.63</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted</p></td><td style="vertical-align:top"><p>-2.81<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body</strong><strong> </strong><strong>Weight (kg) </strong><sup>%</sup></p></td><td style="vertical-align:top"><p><strong>N = 399</strong></p></td><td style="vertical-align:top"><p><strong>N = 169</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>86.9</p></td><td style="vertical-align:top"><p>87.6</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-0.6</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo + metformin (adjusted</p></td><td style="vertical-align:top"><p>-0.1<sup>&para;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>&dagger;</sup> All Patients Treated Population (an intention-to-treat analysis).</p><p><sup>&Dagger;</sup> Least squares means adjusted for prior antihyperglycemic therapy and baseline value.</p><p><sup>&sect;</sup> p&lt;0.001 compared to placebo + metformin.</p><p><sup>%</sup> All Patients as Treated (APa T) population, excluding da ta following glycemic rescue therapy.</p><p><sup>&para;</sup> Not statistically significa nt (p&sup3;0.05) compared to placebo + metformin.</p><p>&nbsp;</p><p>Figure 3: 24-hour Plasma Glucose Profile after 4-Week Treatment with Sitagliptin 50-mg BID and Metformin or</p><p><strong>Placebo and Metformin in Patients with Type 2 Diabetes</strong><strong>&dagger;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:rect id="_x0000_s1300"
  style='position:absolute;margin-left:161.65pt;margin-top:9.95pt;width:21pt;
  height:4pt;z-index:251655168;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1030" type="#_x0000_t75"
      style='width:21pt;height:4.5pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image020.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1302" style='position:absolute;margin-left:283.5pt;
  margin-top:9.95pt;width:14pt;height:4pt;z-index:251657216;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1032" type="#_x0000_t75"
      style='width:14.25pt;height:4.5pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image021.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1301" style='position:absolute;margin-left:220.15pt;
  margin-top:9.95pt;width:14pt;height:4pt;z-index:251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1031" type="#_x0000_t75"
      style='width:13.5pt;height:4.5pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image022.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="32" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image023.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="22" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image024.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="23" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>240</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1312" style='position:absolute;left:0;text-align:left;
 margin-left:130.2pt;margin-top:-12pt;width:319.95pt;height:176pt;z-index:251667456;
 mso-position-horizontal-relative:page' coordorigin="2604,-240" coordsize="6399,3520"
 o:allowincell="f">
 <v:shape id="_x0000_s1313" type="#_x0000_t75" style='position:absolute;left:2872;
  top:-62;width:320;height:80;mso-position-horizontal-relative:page'
  o:allowincell="f">
  <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image026.png"
   o:title=""/>
 </v:shape><v:shape id="_x0000_s1314" type="#_x0000_t75" style='position:absolute;
  left:2932;top:189;width:180;height:80;mso-position-horizontal-relative:page'
  o:allowincell="f">
  <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image027.png"
   o:title=""/>
 </v:shape><v:shape id="_x0000_s1315" type="#_x0000_t75" style='position:absolute;
  left:2604;top:-241;width:6400;height:3520;mso-position-horizontal-relative:page'
  o:allowincell="f">
  <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image028.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="427" height="235" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image029.png" />230</p><p>220</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1318" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:98.4pt;margin-top:1.85pt;width:11.8pt;height:109.95pt;
 z-index:251670528;mso-position-horizontal-relative:page' o:allowincell="f"
 filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.95pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;punctuation-wrap:simple;
    mso-line-break-override:restrictions'><span style='font-size:8.5pt;
    font-family:"Arial",sans-serif;letter-spacing:-.4pt'>Mean</span><span
    style='font-size:8.5pt;font-family:"Arial",sans-serif;letter-spacing:-.6pt'>
    </span><span style='font-size:8.5pt;font-family:"Arial",sans-serif;
    letter-spacing:-.4pt'>Plasma</span><span style='font-size:8.5pt;font-family:
    "Arial",sans-serif;letter-spacing:-.55pt'> </span><span style='font-size:
    8.5pt;font-family:"Arial",sans-serif;letter-spacing:-.4pt'>Glucose</span><span
    style='font-size:8.5pt;font-family:"Arial",sans-serif;letter-spacing:-.55pt'>
    </span><span style='font-size:8.5pt;font-family:"Arial",sans-serif;
    letter-spacing:-.4pt'>(mg/dL)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="20" height="150" alt="Text Box: Mean Plasma Glucose (mg/dL)" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image030.png" />210</p><p>200</p><p>190</p><p>180</p><p>170</p><p>160</p><p>150</p><p>140</p><p>130</p><p>120</p><p>110</p><p>100</p><p><!--[if gte vml 1]><o:wrapblock><v:rect
  id="_x0000_s1303" style='position:absolute;margin-left:168.5pt;margin-top:15.45pt;
  width:14pt;height:11pt;z-index:251658240;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:11.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1033" type="#_x0000_t75"
      style='width:13.9pt;height:11.25pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image031.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1305" style='position:absolute;margin-left:225.1pt;
  margin-top:15.3pt;width:12pt;height:4pt;z-index:251660288;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1035" type="#_x0000_t75"
      style='width:11.85pt;height:4.15pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image032.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1307" style='position:absolute;margin-left:293.25pt;
  margin-top:15.3pt;width:12pt;height:4pt;z-index:251662336;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1037" type="#_x0000_t75"
      style='width:11.65pt;height:3.9pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image033.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1309" style='position:absolute;margin-left:350.35pt;
  margin-top:15.45pt;width:15pt;height:11pt;z-index:251664384;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:11.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1039" type="#_x0000_t75"
      style='width:15pt;height:11.25pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image034.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1311" style='position:absolute;margin-left:424.2pt;
  margin-top:15.3pt;width:21pt;height:4pt;z-index:251666432;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1041" type="#_x0000_t75"
      style='width:21pt;height:4.15pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image035.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1310" style='position:absolute;margin-left:384.3pt;
  margin-top:15.3pt;width:10pt;height:4pt;z-index:251665408;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1040" type="#_x0000_t75"
      style='width:9.75pt;height:4.15pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image036.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1308" style='position:absolute;margin-left:316.05pt;
  margin-top:15.3pt;width:12pt;height:4pt;z-index:251663360;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1038" type="#_x0000_t75"
      style='width:11.65pt;height:3.9pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image037.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1306" style='position:absolute;margin-left:247.75pt;
  margin-top:15.3pt;width:12pt;height:4pt;z-index:251661312;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1036" type="#_x0000_t75"
      style='width:11.85pt;height:4.15pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image038.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><v:rect id="_x0000_s1304" style='position:absolute;margin-left:190.95pt;
  margin-top:15.3pt;width:12pt;height:4pt;z-index:251659264;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:4.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><span
     style='font-size:12.0pt'><v:shape id="_x0000_i1034" type="#_x0000_t75"
      style='width:11.75pt;height:3.9pt'>
      <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image039.png"
       o:title=""/>
     </v:shape><o:p></o:p></span></p>
     <p class=MsoNormal><span style='font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td rowspan="2" style="vertical-align:top"><img width="22" height="19" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image040.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="20" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image041.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="20" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image042.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="20" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image043.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="20" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image044.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="20" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image045.png" /></td><td>&nbsp;</td><td rowspan="2" style="vertical-align:top"><img width="24" height="19" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image046.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="18" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image047.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="32" height="10" alt="Text Box:  

" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image048.png" /></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>Time</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1316" style='position:absolute;left:0;text-align:left;
 margin-left:107pt;margin-top:7.2pt;width:54pt;height:5pt;z-index:251668480;
 mso-position-horizontal-relative:page' o:allowincell="f" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><!--[if gte vml 1]><v:shape id="_x0000_i1042"
     type="#_x0000_t75" style='width:54pt;height:5.25pt'>
     <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image049.png"
      o:title=""/>
    </v:shape><![endif]--><img width="72" height="7" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image050.png" /></p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:rect id="_x0000_s1317" style='position:absolute;
 left:0;text-align:left;margin-left:292.05pt;margin-top:7.35pt;width:54pt;
 height:5pt;z-index:-251646976;mso-position-horizontal-relative:page'
 o:allowincell="f" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><!--[if gte vml 1]><v:shape id="_x0000_i1043"
     type="#_x0000_t75" style='width:54pt;height:4.5pt'>
     <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image051.png"
      o:title=""/>
    </v:shape><![endif]--><img width="72" height="6" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image052.png" /></p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>Sitagliptin and Metformin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo and Metformin</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><sup>&dagger;</sup>Patients with inadequate glycemic control on metformin monotherapy.</p><p>Sitagliptin Add-on Therapy in Patients Inadequately Controlled on the Combination of Metformin without extended release and Glimepiride:</p><p><strong>&nbsp;</strong></p><p>A total of 441 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo- controlled study designed to assess the efficacy of sitagliptin 100 mg once daily compared to placebo in combination with glimepiride (alone or in combination with metformin). In this study, 220 patients were on the combination of glimepiride (&ge; 4 mg per day) and metformin (&ge; 1500 mg per day)</p><p>The combination of sitagliptin, glimepiride, and metformin provided significant reduction from baseline in HbA1c (-0.89%) and FPG (-1.15 mmol/L) compared to placebo (see Table 4). Mean reductions from baseline in HbA1c compared&nbsp;with placebo&nbsp;were&nbsp;generally&nbsp;greater&nbsp;for&nbsp;patients&nbsp;with higher&nbsp;baseline&nbsp;HbA1c values.</p><p>&nbsp;</p><p><strong>Table 4</strong></p><p><strong>Glycemic* Parameters and Body Weight at Final Visit (24-Week Study)</strong></p><p><strong>for Sitagliptin as Add-on Combination Therapy with Glimepiride and Metformin</strong><strong>&dagger;</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong></p><p><strong>100</strong><strong> </strong><strong>mg</strong></p><p><strong>+ Glimepiride</strong></p><p><strong>+ Metformin</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+</strong></p><p><strong>Glimepiride</strong></p><p><strong>+ Metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 115</strong></p></td><td style="vertical-align:top"><p><strong>N = 105</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.27</p></td><td style="vertical-align:top"><p>8.28</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.59</p></td><td style="vertical-align:top"><p>0.30</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.89<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients (%) achieving HbA1c &lt;7%</p></td><td style="vertical-align:top"><p>26 (22.6)</p></td><td style="vertical-align:top"><p>1 (1.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>FPG </strong><strong>(mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 115</strong></p></td><td style="vertical-align:top"><p><strong>N = 109</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>9.96</p></td><td style="vertical-align:top"><p>9.94</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.43</p></td><td style="vertical-align:top"><p>0.72</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-1.15<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body</strong><strong> </strong><strong>Weight</strong><strong> </strong><strong>(kg)</strong><sup>%</sup></p></td><td style="vertical-align:top"><p><strong>N = 102</strong></p></td><td style="vertical-align:top"><p><strong>N = 74</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>86.5</p></td><td style="vertical-align:top"><p>84.6</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>-0.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>1.1<sup>&dagger;&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>value. thera py.</p><p>&nbsp;</p><p>*Primary&nbsp;and secondary&nbsp;glycemic&nbsp;parameters measured&nbsp;included HbA1c and fasting glucose</p><p><sup>&dagger;</sup> All Patients Treated Population (an intention-to-treat analysis).</p><p><sup>&Dagger;</sup> Least squares means adjusted for prior antihyperglycemic therapy status and baseline</p><p>&nbsp;</p><p><sup>&sect;</sup> p&lt;0.001 compared to placebo.</p><p><sup>%</sup> All Patients as Treated (APaT) population, excluding data following glycemic rescue</p><p><sup>&dagger;&dagger;</sup>p=0.007 compared to placebo.</p><p>&nbsp;</p><p>Sitagliptin Add-on Therapy in Patients Inadequately Controlled on the Combination of Metformin without extended release and Insulin:</p><p><strong>&nbsp;</strong></p><p>A total of 641 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo- controlled study designed to assess the efficacy of sitagliptin 100 mg once daily in combination with a stable dose of insulin. Approximately 75% of patients were a lso taking metformin. Patients on pre-mixed, long-acting or intermediate acting insulin (with or without metformin) were randomized to the addition of either 100&nbsp;mg of&nbsp;sitagliptin&nbsp;or placebo. Glycemic endpoints measured included HbA1c, fasting glucose and 2-hour postprandial glucose (PPG).</p><p>&nbsp;</p><p>The combination&nbsp;of sitagliptin, metformin and insulin&nbsp;provided significant improvements in HbA1c, fasting glucose and 2-hour PPG compared to placebo (Ta ble 5). The improvement in HbA1c compared to placebo was generally consistent across subgroups defined by gender, age, race, baseline BMI, length of time since diagnosis of diabetes, presence of metabolic syndrome, or standard indices of insulin resistance (HOMA-IR) or insulin secretion (HOMA-&beta;). There was no meaningful change from baseline in body weight in either group.</p><p>&nbsp;</p><p><strong>Table 5</strong></p><p><strong>Glycemic Parameters and Body Weight at Final Visit (24-Week Study)</strong></p><p><strong>for Sitagliptin as Add-on Combination Therapy with Metformin and a Stable Dose of Insulin</strong><strong>&dagger;</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong></p><p><strong>100</strong><strong> </strong><strong>mg</strong></p><p><strong>+ Insulin</strong></p><p><strong>+ Metformin</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>+ </strong><strong>Insulin</strong></p><p><strong>+ Metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 223</strong></p></td><td style="vertical-align:top"><p><strong>N = 229</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.73</p></td><td style="vertical-align:top"><p>8.60</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.66</p></td><td style="vertical-align:top"><p>-0.13</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;,</sup> <sup>&sect;</sup>)</p></td><td style="vertical-align:top"><p>-0.53<sup>%</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients (%) achieving HbA1c &lt;7%</p></td><td style="vertical-align:top"><p>32 (14.3)</p></td><td style="vertical-align:top"><p>12 (5.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fasting</strong><strong> </strong><strong>glucose</strong><strong> </strong><strong>(mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 225</strong></p></td><td style="vertical-align:top"><p><strong>N = 229</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>9.7</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-1.2</p></td><td style="vertical-align:top"><p>-0.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-1.0<sup>%</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2-hour</strong><strong> </strong><strong>PPG (mmol/L)</strong></p></td><td style="vertical-align:top"><p><strong>N = 182</strong></p></td><td style="vertical-align:top"><p><strong>N = 189</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>15.4</p></td><td style="vertical-align:top"><p>15.4</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (a djusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-2.1</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-2.2<sup>%</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body</strong><strong> </strong><strong>Weight (kg) </strong><sup>&para;</sup></p></td><td style="vertical-align:top"><p><strong>N = 201</strong></p></td><td style="vertical-align:top"><p><strong>N = 200</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.9</p></td><td style="vertical-align:top"><p>88.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (adjusted mean<sup>&Dagger;</sup>)</p></td><td style="vertical-align:top"><p>-0.1<sup>#</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>&dagger;</sup> All Patients Treated Population (an intention-to-treat analysis).</p><p><sup>&Dagger;</sup> Least squares mean adjusted for insulin use at Visit 1 (premixed vs. non-pre-mixed [intermediate- or long-acting]), and baseline value.</p><p><sup>&sect;</sup> Treatment by insulin stratum interaction was not significant (p &gt; 0.10).</p><p><sup>%</sup> p&lt;0.001 compared to placebo.</p><p><sup>&para;</sup> All Patients as Treated (APa T) population, excluding da ta following glycemic rescue thera py.</p><p><sup>#</sup> Not statistically significant (p&sup3;0.05) compared to placebo.</p><p>In another 24-week, randomized, double-blind, pla cebo-controlled study designed to assess the insulin- sparing efficacy of sitagliptin as add-on combination therapy, 660 patients with inadequate glycemic control on insulin glargine with or without metformin (&ge;1500 mg per day) were ra ndomized to the addition of either 100 mg of sitagliptin (N=330) or placebo (N=330), administered once daily while undergoing intensification of insulin therapy. Among patients taking metformin, baseline HbA1c was 8.70% and baseline insulin dose was 37 IU/day. Pa tients were instructed to titrate their insulin gla rgine dose based on fingerstick fasting glucose values. Secondary study-endpoints included HbA1c and FPG.</p><p>&nbsp;</p><p>Among patients taking metformin, at Week 24, the increase in daily insulin dose was smaller in patients treated with sita gliptin (19 IU/day, N=285) than in patients treated with placebo (24 IU/day, N=283). This difference was statistically significant (p=0.007).</p><p>Rega&nbsp;rding&nbsp;secondary&nbsp;study-endpoints&nbsp;there&nbsp;was&nbsp;a&nbsp;reduction in HbA1c for&nbsp;patients treated&nbsp;with&nbsp;sitagliptin, metformin, and insulin of -1.35% compared to -0.90% for patients treated with placebo, metformin, and insulin, a difference of -0.45% [95% CI: -0.62, -0.29]. The reduction in FPG for patients treated with sita gliptin, metformin, and insulin was -3.0 mmol/L compared to -2.4 mmol/L for patients treated with placebo, metformin, and insulin, a difference of -0.7 mmol/L [95% CI: -1.0, -0.3].</p><p>&nbsp;</p><p>Glipizide-Controlled Study in Combination with Metformin without extended release</p><p><strong>&nbsp;</strong></p><p>Long-term maintenance of effect was evaluated in a 52-week, double-blind, glipizide-controlled trial in</p><p>patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy at &ge;1500mg/day.</p><p>&nbsp;</p><p>In this study, patients were randomized to the addition of either sitagliptin 100 mg daily (N = 588) or glipizide (N = 584) for 52 weeks. Patients receiving glipizide were given an initial dosage of 5 mg/day and then electively titrated by the investigator<u> </u>to a target FPG of &lt;110 mg/dL, without significant hypoglycemia, over the next 18 weeks. A maximum dosage of 20 mg/day was allowed to optimize glycemic control. Thereafter, the glipizide dose was to have been kept constant. The mean dose of glipizide after the titration period was 10.3 mg.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1319" style='position:absolute;
 left:0;text-align:left;margin-left:148pt;margin-top:89.3pt;width:3.2pt;
 height:2.4pt;z-index:-251644928;mso-position-horizontal-relative:page'
 coordorigin="2960,1786" coordsize="64,48" o:allowincell="f">
 <v:shape id="_x0000_s1320" style='position:absolute;left:2960;top:1786;
  width:64;height:48;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,48" o:allowincell="f"
  path="m64,32hhl,32,,48r64,l64,32xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1321" style='position:absolute;left:2960;top:1786;
  width:64;height:48;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="64,48" o:allowincell="f"
  path="m64,hhl,,,16r64,l64,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="3" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image053.png" />Both treatments resulted in a statistically significant improvement in glycemic control from baseline. After 52 weeks, the reduction from baseline in HbA1c was 0.67% for sitagliptin 100 mg daily and 0.67% for glipizide, confirming comparable efficacy of the two agents. The reduction in FPG was 0.56 mmol/L for sita gliptin and 0.42 mmol/L for glipizide. In a post-hoc analysis, patients with higher baseline HbA1c (&ge;9%) in&nbsp;both&nbsp;groups&nbsp;had&nbsp;greater&nbsp;reductions&nbsp;from&nbsp;baseline in HbA1c (sita&nbsp;gliptin,&nbsp;-1.68%;&nbsp;glipizide,&nbsp;-1.76%).&nbsp;In this study, the proinsulin to insulin ratio, a marker of efficiency of insulin synthesis and release, improved with sita gliptin and deteriorated with glipizide trea tment. The incidence of hypoglycemia in the sita gliptin group (4.9%) was significantly lower than that in the glipizide group (32.0%). Patients treated with sitagliptin exhibited a significant mean decrease from baseline in body weight compared to a significant weight ga in in patients administered glipizide (-1.5 kgvs. +1.1 kg).</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>The prospective randomized (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:</p><p>-&nbsp; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1000 patient-years) versus diet alone (43.3 events/1000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1000 patient- years), p=0.0034.</p><p>- a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/1000 patient-years, p=0.017.</p><p>- a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1000 patient- years versus diet alone 20.6 events/1000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1000 patient-years (p=0.021).</p><p>-&nbsp;&nbsp; a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1000 patient-years, diet alone 18 events/1000 patient-years (p=0.01).</p><p>&nbsp;</p><p>TECOS Cardiovascular Safety Study</p><p><strong>&nbsp;</strong></p><p>The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized study in 14,671 patients in the intention-to-treat population with an HbA1c of &ge;6.5 to 8.0% with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was &ge;30 and</p><p>&lt;50 mL/min/1.73 m<sup>2</sup>) or placebo (7,339) added to usual care targeting regional standards for HbA1c and CV risk factors. Pa tients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> were not to be enrolled in the study. The study included 2,004 patients who were &ge;75 years of a ge and 3,324 patients who had renal impairment (eGFR</p><p>&lt;60 mL/min/1.73 m<sup>2</sup>).</p><p>&nbsp;</p><p>Patients in the sitagliptin group received fewer antihyperglycemic agents than did those in the placebo group (hazard ratio 0.72; 95% CI, 0.68 to 0.77; p&pound;0.001) and, among patients not on insulin at study entry, were less likely to start chronic insulin therapy (hazard ratio 0.70; 95% CI, 0.63 to 0.79; p&lt;0.001).</p><p>The primary cardiovascular endpoint was a composite of the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Secondary cardiovascular endpoints included the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; first occurrence of the individual components of the primary composite; all- cause mortality; and hospital admissions for congestive heart failure.</p><p>&nbsp;</p><p>After a median follow up of 3 years, sita gliptin, when added to usual care, did not increase the risk of major adverse cardiovascular events or the risk of hospitalization for heart failure in patientswith type 2 diabetes (Table 6).</p><p>&nbsp;</p><p>Table 6</p><p><strong>Rates of Composite Cardiovascular Outcomes and Key Secondary Outcomes</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>100</strong><strong> </strong><strong>mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>p- </strong><strong>value</strong><sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Incidenc </strong><strong>e&nbsp; Rate</strong></p><p><strong>per 100 Patient- Years</strong>*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Incidenc </strong><strong>e&nbsp; Rate</strong></p><p><strong>per 100 Patient- Years</strong>*</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hazard Ratio (95% CI)</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Analysis</strong><strong> </strong><strong>in the</strong><strong> </strong><strong>Intention-to-Treat Population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>7,332</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>7,339</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary Composite</strong><strong> </strong><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(Cardiovascular&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; death,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nonfatal</p><p>myocardial infarction, nonfatal stroke, or hospitalization for unstable angina)</p></td><td style="vertical-align:top"><p>839</p><p>(11.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.1</p></td><td style="vertical-align:top"><p>851</p><p>(11.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.2</p></td><td style="vertical-align:top"><p>0.98</p><p>1.08)</p></td><td style="vertical-align:top"><p>(0.89&ndash;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Secondary</strong><strong> </strong><strong>Composite</strong><strong> </strong><strong>Endpoint</strong></p><p>(Cardiovascular&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; death,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nonfatal</p><p>myocardial&nbsp; infarction&nbsp;&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp; nonfatal</p></td><td style="vertical-align:top"><p>745</p><p>(10.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.6</p></td><td style="vertical-align:top"><p>746</p><p>(10.2)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.6</p></td><td style="vertical-align:top"><p>0.99</p><p>1.10)</p></td><td style="vertical-align:top"><p>(0.89&ndash;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&lt;0.001</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Secondary</strong><strong> </strong><strong>Outcome</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p>380 (5.2)</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>366 (5.0)</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>(0.89-</p></td><td style="vertical-align:top"><p>0.711</p></td></tr><tr><td style="vertical-align:top"><p>All myocardial infarction (fatal and non-</p></td><td style="vertical-align:top"><p>300 (4.1)</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>316 (4.3)</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.95</p></td><td style="vertical-align:top"><p>(0.81&ndash;</p></td><td style="vertical-align:top"><p>0.487</p></td></tr><tr><td style="vertical-align:top"><p>All stroke (fa tal and non-fatal)</p></td><td style="vertical-align:top"><p>178 (2.4)</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>183 (2.5)</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.97</p></td><td style="vertical-align:top"><p>(0.79&ndash;</p></td><td style="vertical-align:top"><p>0.760</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for unstable angina</p></td><td style="vertical-align:top"><p>116 (1.6)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>129 (1.8)</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.90</p></td><td style="vertical-align:top"><p>(0.70&ndash;</p></td><td style="vertical-align:top"><p>0.419</p></td></tr><tr><td style="vertical-align:top"><p>Death from a ny cause</p></td><td style="vertical-align:top"><p>547 (7.5)</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>537 (7.3)</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>1.01</p></td><td style="vertical-align:top"><p>(0.90&ndash;</p></td><td style="vertical-align:top"><p>0.875</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for heart failure<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>228 (3.1)</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>229 (3.1)</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.00</p></td><td style="vertical-align:top"><p>(0.83&ndash;</p></td><td style="vertical-align:top"><p>0.983</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Incidence rate per 100 patient-years is calculated as 100 &times; (total number of patients with &ge;1 event during</p><p>eligible exposure period per total patient-years of follow-up).</p><p><sup>&dagger;</sup> Based on a Cox model stratified by region. For composite endpoints, the p-values correspond to a test of non- inferiority seeking to show that the hazard ratio is less than 1.3. For all other endpoints, the p-values correspond to a test of differences in hazard rates.</p><p><sup>&Dagger;</sup> The analysis of hospitalization for heart failure was adjusted for a history of heart failure at baseline.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of a study in healthy subjects demonstrated that the Janumet XR (sita gliptin/metformin HCl extended-release) 50 mg/500 mg and 100 mg/1000 mg ta blets, and coadministration of corresponding doses of sitagliptin (JANUVIA<sup>&trade;</sup>) and metformin hydrochloride extended-release as individual tablets are bioequivalent.</p><p>&nbsp;</p><p>Bioequivalence between two Janumet XR 50 mg/500 mg tablets a nd one Ja numet XR 100 mg/1000 mg tablet was a lso demonstrated.</p><p>&nbsp;</p><p>In a crossover study in healthy subjects, the AUC a nd Cmax for sita gliptin and AUC for metformin after administration of a single Janumet XR 50 mg/500 mg tablet probe formulation and administration of a single Janumet (sitagliptin phosphate/metformin HClwithout extended release) 50 mg/500 mg tablet were simila r. After administration of a single Janumet XR 50 mg/500 mg tablet probe formulation, the mean Cmax value for metformin&nbsp;was 30% lower and the median Tmax value occurred 4&nbsp;hours later compared with corresponding values after administration of a single Janumet 50 mg/500 mg tablet, which is consistent with the expected modified-release characteristics for metformin associated with the Janumet XR formulation.</p><p>&nbsp;</p><p>After administration of two Janumet XR 50 mg/1000 mg tabletsonce daily with the evening meal for 7 days in healthy adult subjects, steady-state for sitagliptin and metformin was reached by Day 4 and 5, respectively. The median Tmax values for sitagliptin and metformin at steady state were approximately 3</p><p>&nbsp;</p><p>and 8 hours postdose, respectively. The median Tmax values for sitagliptin and metformin after administration of a single tablet of Janumet were 3 and 3.5 hours postdose, respectively.</p><p>&nbsp;</p><p>Pharmacokinetic data that characterize distribution, metabolism and elimination of metformin and sita gliptin were obta ined from studies with administration of the individual components of metformin without extended releaseand sitagliptin, and they are applicable to Ja numet XR.</p><p>&nbsp;</p><p>Absorption</p><p>Janumet <em>XR</em></p><p>After administration of Janumet XR tablets with a high-fa t breakfast, the AUC for sita gliptin was not altered. The mean Cmax was decreased by 17%, although the median Tmax was unchanged relative to the fa sted sta te. After administration of Janumet XR with a high-fa t brea kfast, the AUC for metformin increased 62%, the Cmax for metformin decreased by 9%, and the median Tmax for metformin occurred 2 hours later relative to the fasted state.</p><p><em>Sitagliptin phosphate</em></p><p>The absolute bioavailability of <em>sitagliptin </em>is approximately 87%. Coadministration of a high-fat meal with sitagliptin phosphate had no effect on the pharmacokinetics of sitagliptin.</p><p>&nbsp;</p><p>Distribution</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>The mean volume of distribution at steady state following a single 100-mg intra venous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Distribution studies with extended-release metformin have not been conducted. The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg without extended release averaged 654 &plusmn; 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady state plasma concentrations of metformin are reached within 24-48 hours and are genera <strong>l</strong>y</p><p>&lt;1 mcg/mL. During controlled clinical tria ls of metformin, maximum metformin pla sma levels did not exceed 5 mcg/mL, even at maximum doses.</p><p>&nbsp;</p><p>Metabolism</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>Sita gliptin is prima rily eliminated unchanged in urine, and metabolism is a minor pathway. Approximately 79% of sitagliptin is excreted unchanged in the urine.</p><p>&nbsp;</p><p>Following a [<sup>14</sup>C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin. <em>In vitro </em>studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor bilia ry excretion.</p><p>&nbsp;</p><p>Elimination</p><p>&nbsp;</p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>Following administration of an oral [<sup>14</sup>C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2 following a&nbsp;100-mg oral dose of sita gliptin&nbsp;was approximately 12.4 hours a nd renal cleara nce was approximately 350 mL/min.</p><p>&nbsp;</p><p>Elimina tion of sita gliptin occurs prima rily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human orga nic anion transporter-3 (hOAT-3), which may be involved in the renal elimina tion of sita gliptin. The clinica l releva nce of hOAT-3 in sitagliptin transport has not been established. Sitagliptin is a lso a substrate of p-glycoprotein, which may also be involved in mediating the renal elimina tion of sita gliptin. However, cyclosporine, a p-glycoprotein inhibitor, did not reduce the renal clea rance of sitagliptin.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration of metformin without extended release, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal Impairment</p><p><strong><em>&nbsp;</em></strong></p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>An approximately 2-fold increase in the pla sma AUC of sita gliptin was observed in patients with moderate renal impairment with eGFR of 30 to &lt;45 mL/min/1.73 m<sup>2</sup>, and an approximately 4-fold increase was observed in patients with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m<sup>2</sup>) including patients with end-stage renal disease (ESRD) on hemodialysis, as compared to subjects with normal renal function.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>In patients with decreased renal function, the plasma and blood half-life of metformin without extended release is prolonged and the renal clearance is decreased (see <strong>CONTRAINDICATIONS </strong>and <strong>SPECIAL </strong><strong>WARNINGS AND PRECAUTIONS FOR USE</strong>).</p><p>&nbsp;</p><p>Hepatic Impairment</p><p><strong><em>&nbsp;</em></strong></p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and Cmax of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sita gliptin phosphate. These differences are not considered to be clinica lly meaningful.</p><p>&nbsp;</p><p>There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score &gt;9). However, because sitagliptin is prima rily rena lly eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Use in the elderly Sitagliptin phosphate</em></p><p>&nbsp;</p><p>Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Limited da ta from controlled pharmacokinetic studies of metformin without extended release in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half life is prolonged, and&nbsp;Cmax is&nbsp;increased,&nbsp;compared&nbsp;to&nbsp;healthy&nbsp;young&nbsp;subjects.&nbsp;From&nbsp;these&nbsp;data,&nbsp;it&nbsp;a&nbsp;ppears&nbsp;that&nbsp;the&nbsp;change&nbsp;in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see <strong>GLUCOPHAGE <sup>1</sup></strong> prescribing information: <strong>CLINICAL PHARMACOLOGY</strong>, Specia l Popula tions, Geria trics).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Use in children and adolescents</em></p><p>No studies on safety and efficacy with Janumet XR have been performed in children and adolescent patients.</p><p>&nbsp;</p><p><em>Gender</em></p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>Gender had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Metformin pharmacokinetic parameters did not differ significantly between healthy subjects and patients with type 2 dia betes when analyzed according to gender. Simila rly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.</p><p>&nbsp;</p><p>Race</p><p><strong><em>&nbsp;</em></strong></p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>Race had no clinica lly meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data, including subjects of white, Hispanic, black, Asian, and other racial groups.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>No studies of metformin pharmacokinetic parameters according to race have been performed. In contro <strong>l</strong>ed clinical studies of metformin in patientswith type 2 diabetes, the antihyperglycemic effect wascomparable in whites (n=249), blacks (n= 51), and Hispanics (n=24).</p><p>&nbsp;</p><p>Body Mass Index (BMI)</p><p><strong><em>&nbsp;</em></strong></p><p><em>Sitagliptin phosphate</em></p><p><em>&nbsp;</em></p><p>Body mass index (BMI) had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1026" style='position:absolute;margin-left:71.15pt;margin-top:13.55pt;
  width:2in;height:.8pt;z-index:251672576;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="2880,16" o:allowincell="f"
  path="m2880,hhl,,,15r2880,l2880,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="192" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><sup>1</sup> <strong>GLUCOPHAGE&reg; </strong>is a registered trademark of Merck Sante S.A.S, an associate of Merck KGaA of Darmstadt, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Sitagliptin and Metformin</em></p><p><em>&nbsp;</em></p><p>Preclinica l toxicokinetic and oral toxicity studies with coadministered sita gliptin and metformin without extended release have been conducted in dogs.</p><p>&nbsp;</p><p>In a sixteen-week oral toxicity study, female dogs were administered 20 mg/kg/day of metformin, a lone or in combination with 2, 10, or 50 mg/kg/day of sitagliptin. Transient ataxia and/or tremors were observed in the high-dose combination-treatment group. These signs were considered to be an effect of sitagliptin because they were seen in previous dog studies with sitagliptin alone at 50 mg/kg/day. The no-effect level for trea tment-related changes in this study was 10 mg/kg/day of sitagliptin plus 20 mg/kg/day of metformin, which provided systemic exposure to sitagliptin of approximately 6 times that in patients treated with 100 mg/day of sitagliptin and systemic exposure to metformin of approximately 2.5 times that in patients treated with 2000 mg/day of metformin.</p><p>&nbsp;</p><p>No animal studies have been conducted with the combined products in Janumet XR to evaluate carcinogenesis, mutagenesis, impairment of fertility or effects on reproduction. The following data are findings in studies performed with sita gliptin or metformin individually.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Sitagliptin</em></p><p>Effects in non-clinical studies with rats were observed only at exposures considered sufficiently in excess of the maximum human exposure, indicating little relevance to human use. Sitagliptin has not been demonstrated to be genotoxic or mutagenic in preclinical safety studies.</p><p>&nbsp;</p><p>In a series of repeated-dose toxicity studies in dogs, doses of 2, 10, and 50 mg/kg/day were tested for up to 53 weeks. No effects were found after 53 weeks of treatment at a dose of 10 mg/kg/day, or approximately 6 times the human exposure at the recommended adult human dose of 100 mg/day. In dogs treated with 50 mg/kg/day of sita gliptin (a pproximately 26 times the human dose), transient treatment-related physical signs, including open-mouth brea thing, sa liva tion, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed. In addition, very slight to slight skeletal muscle degeneration was observed histologically in the 14- and 27-week toxicity studies at the 50-mg/kg/day dose. However, no skeletal muscle degeneration was found in the 53-week toxicity study, indicating the lack of reproducibility or progression of this change with increased duration of treatment.</p><p>The systemic exposure at the NOEL in the 53 week study (10 mg/kg/day) was 5 times higher as in the 27 week study (2 mg/kg/day).</p><p>&nbsp;</p><p>Additional 3 month oral toxicity studies were conducted in rhesus and cynomolugus monkeys. The3 month study in the rhesus was conducted to evaluate the potential for sita gliptin to cause skin lesions or kidney toxicity, with evaluations limited to skin and kidney. Monkeys were administered up to 100 mg/kg/day of sita gliptin (28-fold over the systemic exposure following the 100 mg/day clinical dose). There were no treatment-related antemortem or postmortem findings.</p><p>&nbsp;</p><p>In the 3 month oral toxicity study in cynomologus monkeys, routine complete evaluations were conducted. Animals were administered doses up to 100 mg/kg/day of sitagliptin (27-fold over the systemic exposure</p><p>&nbsp;</p><p>following a 100 mg/day clinical dose). There were no treatment-related antemortem or postmortem findings.</p><p>&nbsp;</p><p>Sita gliptin was not carcinogenic in mice when administered orally for 2 years at a maximum-tolerated dose of 500 mg/kg/day. A two-yea r carcinogenicity study was conducted in male a nd female rats given oral doses of sita gliptin of 50, 150, and 500 mg/kg/day. There was an increased incidence of hepatic adenomas and carcinomas in the high-dose males and hepatic carcinomas in the high-dose females. This dose in rats results in approximately 58 times the human exposure based on the recommended daily adult human dose of 100 mg/day. This dose level was associated with hepatotoxicity in rats. The no-observed effect level for induction of hepatic neoplasia was 150 mg/kg/day, approximately 19-fold the human exposure at the 100-mg recommended dose. Since hepatotoxicity has been shown to correlate with induction of hepatic neoplasia in rats, this increased incidence of hepatic tumors in rats was likely secondary to chronic hepatic toxicity at this high dose. The clinical significance of these findings for humans is unknown.</p><p>&nbsp;</p><p>No adverse effects upon fertility were observed in male and female rats given sitagliptin orally at doses up to 1000 mg/kg daily (up to a pproximately 100 times the human exposure based on the recommended daily adult human dose of 100 mg/day) prior to and throughout mating.</p><p>&nbsp;</p><p>Reproductive toxicity studies showed a slight treatment-related increased incidence of fetal rib malformations (absent, hypoplastic and wavy ribs) in the offspring of rats at oral doses of 1000 mg/kg/day. The no-observed effect level for developmental effects was 250 mg/kg/day (32 times the human exposure based on the recommended daily adult human dose of 100 mg/day). Sitagliptin is secreted in the milk of la cta ting ra ts.</p><p>No studies were conducted with sitagliptin, metformin and a sulfonylurea.</p><p>&nbsp;</p><p><em>Metformin hydrochloride</em></p><p><em>&nbsp;</em></p><p>Preclinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propyl gallate, polyethylene glycol, the color indigotine (E132), sodium stearyl fumarate, povidone (K29/32), purified water, hydroxypropylcellulose, hypromellose, colloidal silicon dioxide, macrogol 3350, kaolin, titanium dioxide (E171) and carnauba wax. Janumet XR 50 mg/500 mg tablets contain in addition microcrystalline cellulose.</p><p>Janumet XR 50 mg/1000 mg tablets contain in addition yellow iron oxide (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]--></p><p>Janumet XR 50mg/500mg is supplied in bottles of 56 &amp; 28 film-coated tablets</p><p>Janumet XR 50mg/1000mg is supplied in bottles of 56 &amp; 28 film-coated tablets.</p><p>Janumet XR 100mg/1000mg is supplied in bottles of 28 &amp; 14 film-coated tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Marketing Authorization Holder:
Merck Sharp & Dohme Corp.,
One Merck Drive P.O. Box 100 Whitehouse Station, NJ 08889 United States

Manufacturer:
MSD International GmbH (Puerto Rico Branch) LLC PRIDCO Industrial Park
State Road 183
Las Piedras, Puerto Rico 00771 U.S.A.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>